JDRF 2010 Annual Report · 2015-08-30 · JDRF is committed to delivering better treatments – and ultimately a cure – to people with type 1 diabetes. Over its 40 years, JDRF has

Research Resources

Results

JDRF 2010 Annual Report

JDTable of Contents

Letter from Leadership

Research Milestones

Founder & Founding Members

Research Review 2010

Donor Support

Walk to Cure Diabetes

Gala

Corporate Partners

Major Donors & Partners

Beta Society Members

Stem Cell Research Fund

Named Grants

Financial Report

Chapters & Affiliates

Directors, Chancellors & Senior Staff

2

4

6

8

17

18

20

22

23

42

44

46

47

56

57RF

JDRF is committed to delivering better treatments – and ultimately a cure – to people with type 1 diabetes. Over its

40 years, JDRF has funded $1.5 billion in diabetes research –

more than any other charitable organization. It has become the

largest charitable funder of and advocate for type 1

diabetes research, setting the agenda for diabetes research

worldwide. In FY2010, JDRF funded more than $107 million in research

in 19 countries worldwide, including more than 40 human clinical trials – the final stage of research before

new therapies can reach the people who can benefit from them.

JDRF was founded in 1970 by the parents of children with type 1

diabetes and now has more than 100 locations around the globe. Our supporters share an unrelenting passion and

commitment to improving the lives of all people

with type 1 – and to one day achieving a world free of the disease.

research resources resultsRF

If the past 40 years have proven anything about type 1 diabetes research, it’s that meaningful progress is challenging, but achievable. And when a cure is finally found, JDRF will be the organization that has led the way, from the beginning.

One reason we can say this with confidence is that JDRF-funded research has advanced type 1 diabetes-related science significantly in these 40 years. We are the global leader in driving the translation of research progress into better treatments and an eventual cure for people with type 1 diabetes. Another reason is that 2010 was a pivotal year for achieving important milestones. We are on the cusp of tangible advances that will change the lives of people with type 1 diabetes.

One promising example is a study co-funded by JDRF in which researchers used a sophisticated nanotechnology-based “vaccine” to successfully cure and prevent type 1 diabetes in preclinical models. The study revealed important insights into how to stop the immune attack that causes type 1 diabetes, a critical step along the path toward finding a cure in humans. This approach is now being advanced for testing in people with type 1 diabetes as well as with other autoimmune diseases. You can read more about this study, and about other advances JDRF funding has supported, in the Research Review section.

The nanoparticle vaccine study is just one of many ways JDRF is helping to make progress toward our

fundamental goal of finding a cure. At the same time, we are working hard to gain new insights that can be used to drive the development of therapies to dramatically improve the lives of people with type 1 diabetes until that cure is found. We believe JDRF has an obligation to do all it can to reduce the day-to-day challenges of living with type 1 diabetes, as well as to reverse or even prevent its complications in the near term as we work toward our longer-term goal of a cure.

To ensure that we are allocating our funds to deliver both near-term benefits for people with type 1 diabetes and, ultimately, a cure, we have organized our research program efforts under two main areas: Treatment Therapies, to dramatically reduce the burdens of type 1 diabetes and its complications; and Cure Therapies, to bring about an end to type 1 diabetes once and for all.

Within the Cure area, the focus is on reversing or stalling the immune attack that causes the disease while simultaneously restoring independence from insulin therapy. Within Treatment, our efforts are centered around significantly improving the health and quality of life of people with type 1 diabetes. This new structure will enable us to further speed progress on initiatives with both nearer-term and longer-term projected benefits for us and our loved ones.

And there is good news to report on the fundraising front. Despite a tough economy, we enjoyed a return

Letter from Leadership

Lea

de

rs

hip

i

Jd

rF

02

Frank ingrassia Chairman, Board of directors

Jeffrey Brewer president and Chief executive Officer

More than 80% of JDRF’s expenditures

go directly to research and research-related

education.

RESEARCH RESOURCES

RES

ULT

S

to growth in public support in 2010. In fact, total public support grew by 8 percent from 2009, reaching $194 million. Overall revenues (public support plus investment income) grew to $207 million. This growth was driven by our core programs, such as the Walk to Cure Diabetes, which remains the backbone of JDRF’s fundraising efforts. Walks accounted for $76 million in fundraising support last year, making the JDRF Walk program among the largest and most successful in the world. Special Events and Major Gifts also helped raise support levels, as did fundraising by our International Affiliates.

We take this opportunity to extend our gratitude to our JDRF families, corporate partners, and volunteers, and our broader community of support, who help make our successes possible.

As we look to the future, we continue to grapple with the realities of this disease: millions of people suffer from diabetes and face the devastating complications that accompany the disease, including kidney and heart failure, blindness, stroke, amputation, and dangerously low blood sugar. These truths drive us passionately forward. We are encouraged by recent progress and the opportunities on the horizon. We remain focused on our mission. And we will continue to refine our strategy, as science and circumstance demand, to quicken the pace of meaningful progress and to drive research toward tangible and life-changing benefits for people with type 1 diabetes.

What will this involve?

It will require us to step up our collaborations with the biotechnology and pharmaceutical industry, with the goal of creating clearer paths toward the testing and approval of drugs and devices that benefit people with diabetes.

We will team up with other partners: doctors, nurses, diabetes educators, other foundations, governments, businesses, and scientists. We’ll also be enhancing our results-oriented oversight of the research we fund, creating metrics for success and timetables for progress, while achieving a level of transparency that enables us to drive research faster toward our goals.

What will not change is why we do all this: to dramatically improve the lives of people with type 1 diabetes in the near term; to prevent others from getting type 1 diabetes in the future; and to cure this disease as soon as possible.

A challenge, to be sure.

But with your continued support, we can and will remain true to our promise: to redouble our efforts, to secure all available resources for biomedical research, and to deliver a world without diabetes.

Thank you, as always, for all you do for JDRF and for everyone with type 1 diabetes.

Jdr

F i Lead

er

sh

ip

03

robert Wood Johnson iV Chairman of JdrF international

Mary Tyler Moore international Chairman

susan alberti aO hon LLd international patron

1970sJDRF (then known as the Juvenile Diabetes Foundation) is founded by Lee Ducat and parents of children with type 1 diabetes.

Vitrectomy, an early surgical technique to treat the progression of diabetic eye disease, is pioneered by doctors at a JDRF-funded ophthalmic research center.

Hormones that can beneficially alter the effect of insulin are discovered, purified, and synthesized. One of these, glucagon, becomes an important treatment for hypoglycemia.

JDRF scientists define the tumor angiogenesis factor, the abnormal growth of blood vessels in the eye caused by diabetes.

The first test to measure long-term blood glucose levels – the hemoglobin A1C test – is developed with JDRF backing. Thanks to this test, doctors and scientists can now determine how well someone is controlling diabetes over a period of months.

1980sJDRF-funded science leads to the development of genetically engineered insulin – the first human protein to be cloned and made by genetic engineering.

An experimental insulin pump is developed, delivering a pre-programmed flow of insulin, with larger amounts before meals.

JDRF scientists establish the relationship between low blood sugar and brain metabolism: since the brain cannot store glucose, it is particularly sensitive to rapid and prolonged hypoglycemia.

The relationship between diabetic eye disease and pregnancy is established – an important step in determining preventive measures. Diabetic retinopathy may progress during pregnancy and often reverses after delivery.

JDRF scientists find that blood sugar control is paramount to fetal development, leading to treatment standards that are invaluable to the delivery of babies by women with type 1 diabetes.

Researchers funded by JDRF advance understanding of the cells in blood vessels that are involved in the hardening of the arteries that can result from diabetes.

04

re

sea

rC

h M

iLe

sTO

ne

s

i J

dr

F

1990sTo prevent arteriosclerosis, scientists find that a prototype drug keeps glucose from blocking blood vessels and interacting with leaked plasma proteins.

JDRF research establishes the relationship between diabetic retinopathy and glycosylated hemoglobin levels.

The success rate of pancreatic transplants increases as scientists advance the procedures for transplanting a whole or partial pancreas.

JDRF makes islet transplantation a priority by establishing the JDRF Center for Islet Transplantation at Harvard Medical School, the first of many centers JDRF will launch that focus on reversing type 1 diabetes and hypoglycemic unawareness by replacing insulin-producing cells through transplantation.

JDRF establishes the Human Islet Distribution Programs to meet increased demand for insulin-producing cells for both clinical transplants as well as basic diabetes research.

2000 to presentJDRF helps establish the Immune Tolerance Network.

JDRF researchers develop the Edmonton Protocol for islet transplants, which uses less toxic immune-suppressing drugs.

JDRF partners with the Department of Defense to develop technology to monitor blood sugar.

JDRF research shows that the initial stimulus for diabetic eye disease comes not only from blood vessels but also from the nervous system and the neural components in the retina itself.

A JDRF-funded human clinical trial shows that treating newly diagnosed patients with a drug called an anti-CD3 antibody can preserve the function of insulin-producing cells for several years.

Military, government, academic, and industry researchers work together to develop better methods to deliver insulin and monitor glucose.

Research shows that insulin itself is a key target in the autoimmune attack on pancreatic beta cells.

Clinical trials use new technologies and treatments to reduce the risk of severe hypoglycemia in children.

A large genetics study shows that people with type 1 diabetes who carry a specific gene variant are protected to some degree from diabetic kidney disease.

Researchers discover that adult insulin-producing beta cells have the ability to successfully replicate.

Over 50 genes and genetic regions are identified as the genetic basis of type 1 diabetes.

JDRF-funded human clinical trials definitively show that people with type 1 diabetes who regularly use a continuous glucose monitor experience significant improvements in blood sugar control without increasing their risk for hypoglycemia.

Jdr

F i re

sea

rC

h M

iLes

TOn

es

05

I t was 40 years ago that Lee Ducat fainted upon

learning of her son Larry’s diagnosis of type 1

diabetes. Although devastated, the Philadelphia

mom and her husband, Edwin, were determined to

do all they could to help cure their son and others

with the disease. During a visit to Larry’s doctor

soon thereafter, Lee asked what it would take to

cure the disease. When the doctor replied “funding

for research,” the course was set. That same night –

May 21, 1970 – the Ducats hosted a cocktail party to

raise money for research – and JDRF was born.

That first year, Lee recruited a group of Philadelphia

area parents and guided them in raising $10,000 to

fund research – a triumph for the families who made

up what was then known as the Juvenile Diabetes

foundation (JDF).

Also in 1970, Lee teamed up with Senator Richard

Schweiker in an effort to gain governmental support

for a long-range plan to combat diabetes and

to establish research, treatment, and education

centers throughout the country. “I learned that you

could get more money for research in one day from

the federal government than you could get from

years of fundraising,” says Lee. The result was the

enactment of the first National Diabetes Mellitus

Research and Education Act.

In looking to grow the organization in order to

fund more research, Lee branched out, helping to

form chapters in Miami, Northern New Jersey, and

Washington by 1971.

In 1972, Lee took a step that would profoundly

affect JDF’s future: it was a phone call to New York

City mom Carol Lurie, whose son, Stephen, also had

type 1. Carol and her husband, Erwin, had formed

their own charitable group, bringing together

parents and grandparents of children with type

1 diabetes to raise money to fund research. With

these two charitable families coming together, the

mission of the foundation was set in full motion.

Through the early years of JDF, Lee and Carol each

served as President. Edwin was the first Chairman

of the Board, and took great measures to ensure

the foundation’s early success. Erwin followed suit

as third Chairman of the Board, and he and Carol

proved to be fierce advocates of expanding JDF’s

international presence – we now have affiliates in

Australia, Canada, Denmark, Germany, India, Israel,

Mexico, and the United Kingdom. The tremendous

work of these early leaders – as well as the endless

support and passion of a network of parents

nationally and internationally – have guided JDRF to

become the force it is today.

What started as a mother’s vision to help her

child has now evolved into the largest charitable

funder of and advocate for type 1 diabetes research

worldwide, with $1.5 billion funded in diabetes

research over the past 40 years. JDRF has helped

to ensure strong federal commitment to diabetes

science, and has become the leader in advancing

research toward better treatments and a cure for

people with type 1 diabetes. The foundation has

played a role in most of the advances that have

improved the lives of people with type 1 diabetes

over the past four decades.

A portrait of

Our Founder

and Founding

Members

If Not for Them...

06

Carol Lurie and Lee Ducat

FOu

nd

er

& F

Ou

nd

ing

Me

MB

er

s

i J

dr

F

recognIzIng40 Yearsof Progress

RESEARCH RESOURCES

RES

ULT

S

The hopes, dreams – and hard work – of our founder

and founding members pushed JDRF to expand

nationwide to over 100 chapters and around the

world to eight international affiliates. They shaped

JDRF in countless ways over the years. In recognition

of their vision and leadership, JDRF this year named

three of its highest organizational awards in their

honor: the Lee Ducat Chapter of the Year Award, the

Carol Lurie Affiliate of the Year Award, and the Erwin

Lurie Volunteer of the Year Award.

Sadly, Edwin and Erwin have passed on. However,

since there is still no cure for type 1 diabetes and its

complications, Lee and Carol are still fighting the good

fight, both serving on JDRF’s Board of Chancellors

and supporting the foundation in many ways.

Though Lee and Carol are still as committed as

ever to finding a cure, the scientific advances

over the past 40 years have made them realize

the importance of finding ways to improve the

treatment of type 1 diabetes in the near term.

“I believe that a cure is important, but so is the

amelioration of complications,” says Carol.

For Lee, there are three clear areas of type 1

diabetes research that she feels have made the

most progress in the past 40 years and that hold the

most promise for the future: prevention (possibly

through a vaccine), genetics (discovering new sub-

types of diabetes to allow for better diagnosis and

treatment), and stem cell research (to develop new

beta cells that can replace those destroyed by type 1

diabetes). She views these areas as pathways to the

ultimate goal of a cure.

“I’ve always likened it to a dart board,” Lee says.

“The more you throw the darts, the more likely you

are to hit the bull’s-eye.”

To help scientists speed progress, Lee also

founded the National Disease Research Interchange.

The organization provides scientists with ready

access to the biomaterials – human cells, tissues,

and organs – they need to investigate how diseases

like diabetes develop and progress and how

people who suffer from these diseases can be

treated and cured.

When she surveys the past 40 years of JDRF, Lee

believes that many things have changed – most

noticeably, JDRF’s size.

“But to me, we could never be big enough, because

the bigger we grow, the more darts we’ll have that

could hit the bull’s-eye,” she says.

Still, much about JDRF remains the same as ever,

Lee says.

“When I talk to parents and others deeply involved

at JDRF now,” says Lee, “they’re very much how I

was – love is what propels them day and night.”

Jdr

F i FOu

nd

er

& FO

un

din

g M

eM

Be

rs

07

Top left: Edwin Ducat, first Chairman of the Board. Top right: (Pictured left to right) Carol Lurie, Founding Member; Jacqueline Colvill of Houston, President of JDF, 1979; Lee Ducat, Founder; and Lester Salans, M.D., former Director of NIDDK, and member, first JDF Medical Science Advisory Board. Bottom left: Lee Ducat, Lester Salans, M.D., Carol Lurie. Bottom right: Erwin Lurie, third Chairman of the Board.

The hopes, dreams – and hard work –

of our founder and founding members

pushed JDRF to expand nationwide to

over 100 chapters and around the world

to eight international affiliates.

08

re

sea

rC

h r

eVie

W 2

010

i

Jd

rF

The past year was pivotal for JDRF research – both in numbers and in scientific focus. We funded$107 million in research, and we made significant advances toward new treatments and a cure for type 1 diabetes.

Moreover, as we marked JDRF’s 40th year, we passed a significant milestone, reaching $1.5 billion in cumulative research funding since our founding.

Jdr

F i re

sea

rC

h r

eVieW

20

10

09

That total is surely impressive, but it’s even

more so when put in historical context.

Consider that JDRF (then known as JDF) funded its

first research in 1974: four grants totaling just

over $200,000. Not until 1976 did the foundation’s

research funding surpass $1 million annually,

and as late as 1990, funding totaled just over

$16 million a year.

What this means is that the vast majority of the

$1.5 billion has come in just the last decade –

associated with achieving significant scientific

progress and exciting momentum, as exemplified

by the progress in the field of diabetes research in

the last year. It is thanks in large part to JDRF

funding that the field has blossomed over the past

10 years. New and highly promising areas of

investigation have emerged – beta cell regeneration,

autoantigen-specific immunoregulation, the

technologies that will allow for the development of

first generation artificial pancreas systems – that

were not even considerations a decade ago, let

alone back in 1970. JDRF has aggressively

invested in these areas and helped accelerate

these scientific advances.

Because of the momentum and developments

we have seen in recent years, JDRF remains as

confident as ever that continued funding of

innovative and critical research will result in

advances that will lead to better treatments

and ultimately a cure – and that we will be the

organization driving these developments.

At the same time, the past 40 years have shown

us that curing diabetes will not be easy. It has

become painfully clear that this is a highly

complicated disease, and to cure it, we must solve

multiple problems: We must figure out how to stop

the immune attack that causes diabetes; we must

determine how to regenerate or replace beta cells

so people can make their own insulin again; and we

must stop or reverse complications that may have

already begun.

research revIew 2010

JDRF funds research in

19 countries.

RES

EAR

CH RESOURCES RESULTS

We have come to believe that as we progress

toward these goals, it is vitally important that we

also focus on making life better for people with type

1 diabetes in the short term.

Without losing sight of the ultimate goal of a cure,

JDRF has turned some of its attention to areas we

believe will bring about impactful, tangible

improvements in the lives of people with type 1

diabetes in the near term – areas like achieving

better blood sugar control to protect against

complications. By doing so, we will help people with

diabetes live as long and healthily as possible as we

continue to search for a cure.

We have reorganized our research focus around

those two distinct, but related aims: science leading

to a cure, and science leading to better treatments.

This research review is organized in the same way,

highlighting progress across the past year in Cure

Therapies and in Treatment Therapies. We have also

expanded our Industry Discovery and Development

Partnership program to stimulate company

involvement in, and to support the commercialization

of, targeted type 1 diabetes research projects across

our research portfolio.

Throughout this review, there are common themes

that set JDRF research apart: our proactive

management of science, our ability to foster

collaboration and partnerships between academic

and industry researchers, our targeting of innovative

ideas, and our commitment to accelerating scientific

progress in the area of type 1 diabetes.

New and highly promising

areas of investigation have

emerged that were not even

considerations a decade

ago, let alone in 1970.

10

Cure-related research accounted for about

two-thirds of JDRF’s research funding in FY2010

and included programs and projects in our Beta Cell

Therapies and Immune Therapies portfolios.

Beta Cell Therapies research seeks to

find ways to restore the insulin-producing beta cells

that are lost in the immune system attack that

causes type 1 diabetes. Within this area, pathways

to a cure involve either the regeneration or the

replacement of the insulin-producing beta cells.

Regeneration focuses on triggering the body to

re-grow its own beta cells, and to convert or

reprogram other cells to become beta cells.

Replacement focuses on replacing lost or damaged

beta cells with functional beta cells or their earlier

cell forms from external sources, like organ donors,

animals, or stem cells. Last year, JDRF funded

approximately $35 million in research in this area.

Immune Therapies research seeks to

stop the immune system attack on beta cells that

leads to diabetes in the first place and destroys

newly regenerated or replaced beta cells if it’s not

addressed. Studies supported by the Immune

Therapies program focus on the discovery and

development of novel therapies for halting the

autoimmune response, with strong emphasis on

antigen-specific approaches. The Immune

Therapies program also supports studies to

understand the disease progression in individuals

at risk for type 1 diabetes as well as those with the

established disease – knowledge critical to the

ability to design and optimize immunotherapies at

all type 1 diabetes stages. In FY2010, JDRF funded

more than $32 million in Immune Therapies

research.

FY2010 Progress and Success

Immune TherapiesLong-Term Anti-CD3 Benefits A clinical trial in

Belgium found that a six-day treatment with an

anti-CD3 drug slows the progress of diabetes over

the first few years after diagnosis.

For many years now, JDRF has funded research into

the development of anti-CD3 antibody therapy –

CuRe TheRApIes

www.juvenation.org

re

sea

rC

h r

eVie

W 2

010

i

Jd

rF

Juvenation, JDRF’s online

community for people affected by

type 1 diabetes, has more than 12,000

members.

RESEARCH RESOURCES

RES

ULT

S

compounds engineered to block the function of the

T cells that mediate the immune system attack in

type 1 diabetes. The therapy has been shown to

halt the progression of diabetes in people newly

diagnosed with the disease. This study took that

work a step further by showing that even a brief

treatment at the time of diagnosis of type 1 diabetes

preserved the function of insulin-producing cells

for several years – a major step toward stopping

or slowing diabetes. The trial also pointed to the

importance of early intervention; people who

benefited most from the treatment were younger at

the time of diagnosis and had more remaining beta

cell function.

Phase III Trials Separate research on anti-CD3

treatments progressed to the most advanced stage

of clinical testing: Phase III trials.

Two of JDRF’s industry partners began testing

anti-CD3 treatments in Phase III trials. JDRF partner

MacroGenics and its pharmaceutical collaborator Eli

Lilly and Co. are evaluating the drug teplizumab in a

study of 530 people in 14 countries. JDRF partner

Tolerx and its pharmaceutical collaborator

GlaxoSmithKline are evaluating the drug

otelixizumab in two large Phase III trials at multiple

sites in Europe and North America. The trials

demonstrate the success of JDRF’s strategy to fill

gaps in the drug development pipeline by helping

small companies fund early clinical testing that then

attracts bigger companies to step in and fund the

large trials needed for FDA registration and approval

in the United States.

Recently, MacroGenics and Eli Lilly announced that

one of their trials of teplizumab used to treat

recent-onset type 1 diabetes did not meet its

primary efficacy endpoints during a one-year review.

The companies have decided to suspend further

enrollment and dosing in two other ongoing trials of

the drug in people with type 1 diabetes. This study

was not halted due to safety concerns. MacroGenics

and Eli Lilly are currently reviewing the data from the

trials to better understand the outcome and

determine next steps.

Advances Across Two Diseases JDRF joined

forces with two partners in an innovative bid to stop

the autoimmune dysfunction underlying both type 1

diabetes and multiple sclerosis. The program is

among the first between patient organizations for

different diseases.

JDRF has partnered with Fast Forward – the

drug-development arm of the National Multiple

Sclerosis Society – and Axxam, an Italian company

that is screening its extensive chemical library for

compounds that target immune system ion

channels – tiny tunnels on the surface of cells. It’s

believed that a particular ion channel is involved in

the immune system malfunction that causes both

diseases. With JDRF’s funding, Axxam is identifying

drugs that block the channel, and can be developed

as potential immune therapies.

11

A partnership Beyond ResearchNovo Nordisk

Thanks to Novo Nordisk, JDRF is now reaching people with type 1 diabetes in an entirely new way: via Juvenation, its online social networking site.

It all began in early 2008, when JDRF approached Novo Nordisk with the concept of developing a social networking site

for people with type 1 diabetes, particularly young adults and their families. Novo Nordisk liked the idea because it addressed a pressing problem that had recently been identified in a global survey of kids with diabetes: the lack of social and psychological support in healthcare systems, which resulted in poor disease control and increased risk for long-term health complications.

Novo Nordisk saw Juvenation as a way to address the problem. With its help, JDRF launched the site later in 2008, giving the world its first online social networking site designed for people with type 1 diabetes and their families to come together and share thoughts, tips, and concerns while learning and having some fun, too. By May 2010, Juvenation had reached the impressive milestone of 10,000 members, and it has kept growing by leaps and bounds, adding about 500 new members a month.

Novo Nordisk also collaborates with JDRF in other ways. For instance, it’s been a longstanding supporter of the Ride to Cure Diabetes, sending 26 riders – including President and CEO Lars Rebien Sorensen, an annual participant – to the Death Valley Ride in 2009.

Jdr

F i re

sea

rC

h r

eVieW

20

10

12

Nanoparticle Vaccines Researchers successfully

cured and prevented type 1 diabetes in mice using

an innovative nanotechnology-based vaccine.

JDRF-funded scientists used a vaccine made of

nanoparticles – thousands of times smaller than the

size of a cell – that were coated with proteins

involved in enabling immune cells to communicate

with one another. The treatment increased the

numbers of a type of cell that suppresses the

immune system attack underlying diabetes, and

restored normal blood sugar levels in mice with

the disease. The study, conducted at the University

of Calgary in Alberta, provides important insights

into stopping the immune attack that causes type 1

diabetes. In fact, these discoveries have now

triggered the formation of a company called Parvus

Therapeutics, Inc., which will further develop the

technology. The study also shows the potential of

antigen-specific therapies, which target highly

specific autoimmune responses without damaging

the overall immune system.

Blocking “Natural Killer” Cells Scientists

demonstrated that certain immune system cells

(called regulatory T cells) play a role in preventing

type 1 diabetes.

Researchers at Harvard Medical School showed that

regulatory T cells control how diabetes progresses

in mice. The cells rein in the immune attack on the

pancreas by changing how other immune system

cells – called “natural killer” cells – function. When

there were no regulatory T cells to block them, the

natural killer cells began the immune attack that

causes diabetes. The research suggests that drugs

or therapies targeting these cells could prevent

diabetes or alter its course.

nPOD Expands to Europe JDRF’s nPOD program,

a remarkable success in advancing research into the

causes of type 1 diabetes, was expanded to Europe.

The Network for Pancreatic Organ Donors with

Diabetes – better known as nPOD – provides

diabetes researchers worldwide with access to

pancreatic and other tissues from organ donors at

all stages of diabetes; researchers use the tissues in

studies that seek to answer key questions about the

underlying cause and characteristics of type 1

diabetes. By expanding to Europe, nPOD can offer

researchers an additional pool of potential organ

donors – including the important but less-studied

group with pre-diabetes, a stage of disease prior to

insulin-dependence. nPOD expects to be screening

about 30 percent of all organ donors in the United

States by the end of 2011 – a key milestone for the

program, and a huge help for researchers.

Beta Cell TherapiesRegeneration Partnerships JDRF entered into

three new partnerships to speed the fast-developing

field of regeneration, demonstrating its leadership

in this new and highly promising pathway of

diabetes research. The early-stage research driven

by JDRF has now attracted the attention of large

pharmaceutical companies who are committing

funds and capabilities to accelerate drug

development for beta cell regeneration. JDRF will

continue to explore innovative partnerships and

new funding mechanisms to address gaps in type 1

diabetes research.

• A research collaboration with Pfizer, Hadassah

Medical Organization, and The Hebrew University

of Jerusalem to develop drugs that can regenerate

insulin-producing cells. The program evaluates

Pfizer compounds that promote cell regeneration,

and builds on unique beta cell regeneration

models created by JDRF-funded researchers.

• A unique agreement with the Genomics Institute

of the Novartis Research Foundation (GNF) to

create a drug discovery and development platform

for beta cell proliferation, survival, and

reprogramming. This is one of the largest and

most comprehensive collaborations in JDRF’s

history, and marks a major opportunity to work

with an experienced and highly regarded scientific

partner to quickly translate discoveries in research

into new therapies.

• A collaboration with the Johnson & Johnson

Corporate Office of Science and Technology to

develop drug targets and pathways that promote

The past 40 years have shown us that

curing diabetes will not be easy. This is a

highly complicated disease, and to cure

it, we must solve multiple problems.re

sea

rC

h r

eVie

W 2

010

i

Jd

rF

JDRF is now funding more than 40 trials

in people.

RESEARCH RESOURCES

RES

ULT

S

beta cell survival and function. The program funds

research at academic and medical research

centers worldwide, creating an “incubator” to

support early-stage studies. By working with a

company known for first-class research and

significant experience in the commercialization of

products, JDRF is looking to increase the number

of viable drug targets identified and fundamentally

advance the pace of diabetes research.

Pancreas Cells Change into Insulin-Producing Cells (Reprogramming) Researchers at the University of Geneva in

Switzerland showed that pancreas cells that do not

normally produce insulin hold the potential to

naturally convert into cells that do.

In research in mice, alpha cells in the pancreas –

specialized cells that produce glucagon, not insulin

– can spontaneously convert into insulin-producing

beta cells under specific conditions. The study

showed the potential of these cells to adapt and

produce insulin when needed – in this case, when

the beta cells that normally produce insulin were

destroyed. The results were the first to show that

beta cell reprogramming can occur spontaneously,

without genetic manipulation; scientists may be

able to harness this conversion potential to

regenerate beta cells in people with diabetes. This

may be particularly useful in people who have had

diabetes for a long time and have no, or very few,

remaining beta cells.

Critical Beta Cell Development Gene Identified Scientists identified a gene needed

for cells to mature into insulin-producing cells and

other cell types in the pancreas.

Researchers from the University of California,

San Francisco and McGill University showed that

mice lacking a certain gene were not able to make

insulin-producing cells (or most other cells in

the pancreas). They also found that in people,

newborns who had a deficiency of that gene

eventually developed diabetes. The research

provides important new insights into beta cell

development. Most importantly, it boosts the

prospects for one day being able to generate an

abundant, renewable supply of insulin-producing

cells to replace those killed off by the immune

attack that causes diabetes.

Stress Hormone Linked to Cell GrowthA hormone responsible for the body’s stress

response was linked to the growth of insulin-

producing cells, suggesting new pathways to

restore beta cells and cure diabetes.

When researchers at the Salk Institute for

Biological Studies in California exposed beta cells

to a stress hormone and high levels of sugar, the

cells began to replicate. The findings reinforce the

potential of regeneration as a cure for diabetes, and

provide insights for discovering new approaches to

treat the disease.

13

Jdr

F i re

sea

rC

h r

eVieW

20

10

Mom Leads her hometown to Walk for a CureLisa TaylorThere’s no JDRF chapter in Fredericksburg, VA; the nearest one is a 45-minute drive away in Richmond, the state capital. But that hasn’t stopped local mom Lisa Taylor from building a highly successful Walk in her hometown.

Lisa helped spearhead the creation of the Fredericksburg Walk after moving there from New York City, where she had connected with JDRF after her daughter Elissa was diagnosed with type 1 diabetes at 10 months old. In New York City, Lisa had helped make the Queens Walk a success. After the family moved to Fredericksburg, Lisa got involved in a local type 1 support group for families, and together, some of the parents decided to hold a Walk to raise money for JDRF. That first year, they gathered at the city’s historic Civil War battlefield site and raised $3,000.

The founding families sought out the support of JDRF’s Central Virginia Chapter in Richmond the following year, and Lisa took on the role of volunteer Walk chair. She steered the Fredericksburg Walk to steadily growing success. But after five years in the role, Lisa was finding the job tough, given medical issues she was experiencing at the time. She thought about stepping down.

Then her second daughter, Genaya, was diagnosed with type 1 diabetes at the age of 14 in December 2007. Lisa quickly banished all doubts about continuing in her Walk role. The event has continued to go from strength to strength under her guidance. With her daughters’ help – Elissa is now a 20-year-old college senior and Genaya is a 17-year-old high school senior – Lisa organized the most successful Fredericksburg Walk ever this past year, raising more than $40,000.

Lisa has no intention of stopping now. “As a parent, you want to do anything in your power to help your children,” she explains. “I believe we can get to a cure, and I will do whatever it takes to help us get there.”

Treatment-related research accounted for

one-third of JDRF’s research funding in FY2010

and included programs and projects in our Glucose

Control and Complications Therapies portfolios.

JDRF’s Glucose Control program

encompasses research designed to produce drugs,

devices, and products that can help people with

diabetes better manage their disease. Glucose

Control research is still in its infancy at JDRF, but

over the past five years, JDRF has sped to the

forefront of this area of science, thanks largely to its

Artificial Pancreas Project – a cross-functional effort

to speed the development and use of automated

and semi-automated systems to sense blood sugar

and dispense insulin in response. In FY2010, JDRF

Glucose Control research totaled an estimated

$22 million, approximately 90 percent of which

was committed to various aspects of the Artificial

Pancreas Project.

Complications Therapies research

includes science aimed at preventing, slowing, or

reversing the major complications of diabetes: eye

disease, kidney disease, nerve disease, and

cardiovascular disease. JDRF has been particularly

focused on eye disease, with several major advances

in the past year that are bringing new treatments for

macular edema and retinopathy. In FY2010, JDRF

funded more than $17 million, with approximately

40 percent spent on diabetic eye disease.

FY2010 Progress and Success

Complications TherapiesFirst New Diabetic Eye Disease Treatment in 25 Years A groundbreaking study identified the

first new treatment for people with diabetic eye

disease in the last 25 years. The results show it not

only stops the progress of eye disease, but

improves vision – a huge step up from any other

treatment now available.

The study, a Phase II clinical trial, showed that the

drug Lucentis, when combined with the current

standard treatment of laser therapy, not only slows

the progression of diabetic eye disease but can also

14

17 Years of the paper sneakerTops Friendly Markets and JDRF

The JDRF Sneaker is a well-loved symbol of JDRF’s Walk to Cure Diabetes – and the focus of a nationwide Sneaker Sales campaign that raises $10 million a year for type 1 diabetes research. Like many great fundraising ideas, this one came from a JDRF supporter – namely Tops Friendly Markets, the supermarket chain based in Williamsville, NY.

The Sneaker Sales concept was born in 1993, when JDRF approached Tops about developing a fundraiser for that year’s local Walk to Cure Diabetes. Larry Castellani, then President and CEO of Tops, agreed to sell a dollar item in stores for six weeks leading up to the Walk. With the help of Doug Hartmayer, Tops’ community relations director, creative juices began to flow between Tops and JDRF, and they finally settled on printing cut-out paper footprints to sell to customers for a $1 minimum donation. The program was a big success, so they decided to repeat it the following year. But this time, they thought footwear was more apt than footprints – and designed the paper Sneaker that we all know and love today. Other JDRF chapters caught wind of the idea, and the fundraiser started to grow.

“We became very attached to JDRF,” Hartmayer recalls. “They energized us, and we energized them. They weren’t just asking a corporation to do something; they were there with their sleeves rolled up working side by side with us.”

Since the program’s inception, Tops has raised more than $6.7 million for JDRF. In acknowledgement of the company’s generosity over the years, JDRF recognized Tops at its 2010 Annual Conference in Washington, DC.

Tops’ 132 supermarkets throughout New York and Pennsylvania run fundraisers all year long to support JDRF – everything from bowling events to spaghetti dinners – but the Sneaker program remains the company’s top fundraiser, says Andy Brocato, Hartmayer’s successor, who has been involved with the program at Tops for 13 years.

The company’s commitment remains as strong as ever.

“Our greatest accomplishment has not been achieved yet,” Brocato says. “Our job is to put JDRF out of business. One day we’ll be at your going-away party.”

That’s one “threat” worth celebrating.

TReATMeNT TheRApIes

re

sea

rC

h r

eVie

W 2

010

i

Jd

rF

Is proudly supported by: Is proudly supported by: Is proudly supported by:

15

actually improve vision. The breakthrough is the

result of JDRF research investments over many years

in partnership with Johns Hopkins University School

of Medicine and Genentech, which licenses Lucentis.

Eye Drops for Macular Edema A clinical

trial found that a topical drug slows the progress

of a severe form of diabetic eye disease called

macular edema. Because this potential treatment

can be self-administered, it may also ease the

burdens of healthcare costs and be more readily

used by patients.

Diabetic macular edema is a leading cause of

blindness in adults with diabetes. Researchers at

the Wilmer Eye Institute of Johns Hopkins University

School of Medicine last year completed a multi-

center clinical trial evaluating mecamylamine,

a topical drug developed by JDRF industry partner

CoMentis, Inc. About 40 percent of the people in the

trial showed significant improvement, including in

vision, after using mecamylamine eye drops.

Gene Therapy for Nerve Damage The Phase

III trial of a gene therapy developed by JDRF industry

partner Sangamo BioSciences showed that the

therapy reverses and repairs diabetic nerve disease.

The trial tested a gene therapy to treat nerve

damage in the legs of people with peripheral

sensory neuropathy (a common diabetic

complication that involves small nerve fibers in the

arms and legs, often leading to a loss of sensation

and motor function). The study showed that the

drug can help re-grow nerves by promoting the

production of a specific protein linked to nerve

growth and function. An increase in these proteins

may protect the nerves and repair nerve damage

in people with diabetes. This would be a major

improvement, since current treatments address

only the pain associated with neuropathy.

Glucose ControlArtificial Pancreas Partnerships JDRF’s

Artificial Pancreas Project established several

partnerships with key industry participants to drive

the development of a system to enable people with

type 1 diabetes to achieve tighter blood glucose

management, lead healthier lives, and reduce their

risk for complications.

JDRF entered into an innovative, non-exclusive

partnership with Animas Corp. to develop a

first-generation artificial pancreas – an automated

insulin delivery system – to help people better

control their diabetes. Animas is a Johnson &

Johnson company and a leading pump

manufacturer. JDRF also announced a partnership

with BD (Becton, Dickinson and Co.), aimed at

developing new insulin delivery products to

enhance insulin pumps. Advances in pump

technology will not only lead to improved glucose

control but can also be incorporated into an

artificial pancreas. The partnerships were dramatic

steps on the road to producing a readily available

artificial pancreas.

Avoiding Overnight Lows A first-generation

artificial pancreas showed that it can safely

control the blood sugar of children and teenagers

with diabetes overnight – the most frightening

time for children, teens, and their parents because

of the danger of unrecognized and untreated low

blood sugar.

In a landmark study in children and teenagers with

type 1 diabetes, JDRF researchers at the University

of Cambridge showed that using a first-generation

artificial pancreas system overnight lowers the risk

of low blood sugar emergencies while improving

diabetes control overall. The system maintained the

blood sugar of the participants in safe and healthy

ranges throughout the night, even under a number

of differing conditions and situations, such as after

they had eaten a particularly large dinner or after

they had exercised.

It is vitally important that

we also focus on making life

better for people with type 1

diabetes in the short term.

Jdr

F i re

sea

rC

h r

eVieW

20

10

JDRF has committed more than $70 million to research at 29

companies through its Industry Discovery

and Development Partnership

program.

RES

EAR


16

CGM, Insulin, and Glucagon Researchers

showed that an artificial pancreas system could

successfully integrate hormones like glucagon –

underscoring its potential to replicate all the

functions of the pancreas.

Researchers from Boston University and

Massachusetts General Hospital showed that an

artificial pancreas using two hormones – glucagon

as well as insulin – can lower the risk of low blood

sugar emergencies. Glucagon is a naturally

occurring hormone that counters insulin’s action;

it raises blood sugar when people experience

dangerously low blood glucose levels, or

hypoglycemia. The production of glucagon is

impaired in people with type 1 diabetes. Using an

insulin-plus-glucagon version of the artificial

pancreas, all study participants achieved near-

normal blood sugar levels for more than 24 hours

without experiencing hypoglycemia.

CGM Studies Show Benefits of Regular Use

Researchers confirmed that regular CGM use – six

days per week or more – is the most important factor

in achieving better diabetes control; less important

is the age of the person using the monitor or other

demographic, clinical, or psychosocial factors. A

second JDRF study found that people who continued

using a CGM were able to sustain good control

long-term while experiencing a lower rate of

hypoglycemia, a state of dangerously low blood

sugar that can occur even with tightly managed

type 1 diabetes.

The research underscored the point that CGMs are

more than simply devices of convenience for people

with diabetes – they are tools that can substantially

improve blood sugar control in people of all ages

when used regularly, without increasing the risk of

dangerous low blood sugar. The growing evidence of

CGMs’ benefits highlights the need for continued

research into a closed-loop artificial pancreas, a

system that uses CGM data to automatically deliver

the right amount of insulin at the right time.

pedaling with a purposeJDRF Ride to Cure Diabetes

The JDRF Ride to Cure Diabetes engages bicyclists from around the world to take on two challenges: raising the money needed to fund the research for better treatments and a cure for diabetes; and reaching a personal training goal to prepare them for a destination cycling experience.

JDRF Ride destinations are designed for riders of all fitness levels. JDRF supports riders in each challenge; connecting them with both a USA Cycling certified coach and a JDRF fundraising coach. At each site, riders have professional mechanical support as well as ride support on a well marked and marshaled course. Clinics and training rides precede the Ride, and evening awards dinners recognize the amazing accomplishments of the families and friends that support JDRF’s Ride to Cure Diabetes. The program has raised more than $20 million since its founding in 1998. Last year’s program attracted more than 700 participants from all over the

world to Rides in five spots: Killington, VT; Kansas City, MO; Whitefish, MT; Death Valley, CA; and Tucson, AZ. More than 70 percent of participants in the Ride return each year, raising on average $4,500 each and proving that the experience is both rewarding and life-changing.

Over the past five years,

JDRF has sped to the

forefront of glucose

control research, thanks

largely to its Artificial

Pancreas Project.

“ I have had type 1 diabetes for 39 years, and after completing my first Ride, I felt as if I had just accomplished more than any other single thing I had ever done. That was nine Rides ago. I was hooked; it’s changed my life forever, and I won’t stop riding until there’s a cure.”

– Lorne Shiff Toronto, Canada

re

sea

rC

h r

eVie

W 2

010

i

Jd

rF

As many as 3 million

Americans have type 1 diabetes.

RESEARCH RESOURCES

RES

ULT

S

17

Jdr

F i dO

nO

r s

up

pO

rT

DonorsUPPorT

18

At the very core of this paramount level of achievement is everyone who helps in the Walks’ success, especially the passionately dedicated family and corporate teams.

Every JDRF Walk also creates a special kind of support beyond the dollars raised. Walkers whose lives have been touched by type 1 diabetes come together, building a sense of community and purpose that far surpasses any price.

We are delighted to recognize the family teams that raised $75,000 or more for the Walks in FY2010. These teams listed represent only some of

the countless devoted family and corporate teams, walkers, donors, and volunteers who contribute to the enormous success of the more than 225 Walks held each year.

JDRF’s Walk to Cure Diabetes program is in a league of its own, having raised over $1 billion toward our mission since the program began in 1992, including $86.1 million in FY2010 alone.

dO

nO

r s

up

pO

rT

i

Jdr

F

walk To cUre DIabeTes

The kids at Mesa Middle School in Castle Rock, CO, had a lot to be proud of last year. Working together, they helped their school become the No. 1 online fundraiser

nationwide for the Kids Walk to Cure Diabetes program. Their final tally: more than $13,800 raised online (and more than $18,900 raised overall).

The Mesa students achieved their gold-medal performance by making full use of the new tools launched in 2010 as part of the Kids Walk to Cure Diabetes website. For example, they created personal webpages and e-mailed friends and family asking for support.

The Kids Walk site also provided teachers with lesson plans and educational activities to help students learn more about diabetes and JDRF. It gave families and school personnel tips for making their Walk a success.

English/language arts teacher Katherine Azofeifa led the effort at Mesa and was deeply touched by seeing the kids taking steps – literally and figuratively – to help each other. The Mesa middle schoolers proved that “Kids Helping Kids” isn’t just a motto for the Kids Walk program, but a reality, too.

Congratulations to the FY2010 Family Walk Teams who raised more than $75,000!

Kids Walk Website Takes program to the Next LevelMesa Middle School

Cohn Sisters: Mackenzie’s Miracle Makers & Sydney’s Superstars Eastern Pennsylvania/Delaware Chapter

Team Cure New England/Bay State Chapter

Michael’s Legal Eagles New York City Chapter

Joe’s Impatient WalkersGreater Bay Area Chapter

Tessa’s Troopers Los Angeles Chapter

Punkin’s PeepsNew York City Chapter

Team SudburyNew England/Bay State Chapter

Harmelin Family TeamEastern Pennsylvania/Delaware Chapter

Lizzie’s CrusadersMetro-St. Louis/Greater Missouri Chapter

Mimi’s MarchersLong Island Chapter

McFeeley MarchersCharlotte Chapter

Team JakeTampa Bay Chapter

Charlie’s AngelsLos Angeles Chapter

19

nearly 40 years later, the Cohns were again tapped to help ensure the

success of a JDRF Gala in Philadelphia, serving on the “honorary committee” that helped fundraise for the Eastern Pennsylvania/Delaware Chapter Gala in May 2010. But this time, they had a highly personal reason for volunteering their time: their granddaughters, Sydney and Mackenzie. The girls were both diagnosed with type 1 diabetes at the age of seven and a half – Sydney in the winter of 2007 and Mackenzie in the summer of 2008.

Since the girls’ diagnoses, the entire extended Cohn family has gone all-out to do what Norman and Suzanne helped do in JDRF’s early days: raise money to fund research toward better treatments and a cure for all who live with type 1 diabetes.

Matthew and Lea Cohn, the girls’ parents, say the family is made up of the kind of people who, when faced with a challenge, ask themselves: “What can we do to make things better?”

That philosophy is reflected in the enormous success they’ve had in raising money to fund diabetes research. The family’s Walk team, known as “The Cohn Sisters: Mackenzie’s Miracle Makers and Sydney’s Superstars,” has been the No. 1 family team for three years running now. This past year, the team’s 200 walkers raised nearly $330,000 – putting them over the $1 million mark cumulatively to date.

What’s the secret to their success? “Reaching out to people,” says Matthew. “We ask everybody, all the time. We let people know that we are raising money for diabetes research, and we focus on making sure people are aware.”

The Walk has become an integral part of their lives. “One of the most important things about the Walk is the sense of hope it gives us – and the feeling that we can make a difference,” Lea says.

The Cohns do far more than just participate in the Walk, however. Matthew serves on the Eastern Pennsylvania/Delaware Chapter Board and is a recent addition to JDRF’s International Board of Directors. Both Matthew and Lea serve on their chapter’s Gala and Walk committees. They have donated the leadership “patron gifts” to their local Gala every year since 2007, and they have enlisted the rest of their family members – grandparents, aunts, uncles, cousins – in the cause of raising money for research. As if all that weren’t enough, Matthew recently also took on the role of National Walk Chair.

Matthew and Lea are happy to commit their time to JDRF. For one thing, they credit JDRF with giving them crucial support when their daughters were diagnosed. “There was a time when I could not envision our lives ever being normal again,” Matthew says. But he began to see “the light at the end of the tunnel,” as he called it, when a JDRF family invited the Cohns to their home. “When we went to their house, everything was so normal. It helped me see that our lives could be normal, too.”

Most importantly, Matthew and Lea give their time and treasure to JDRF because they know that their daughters have

benefited from research made possible by those who came before them – including Lee Ducat and Matthew’s parents, Norman and Suzanne. They want to honor those contributions by making their own.

“We are indebted to Lee and to all the other volunteers who came before us,” Lea says. “The research that they helped make possible has made the disease much more manageable.”

Matthew agrees: “We are truly the beneficiaries of all that JDRF has done throughout the years. Today, there is so much promise, so much hope. This is going to be the first chronic disease to be cured. I’m sure of it.”

“ One of the most important things about the Walk is the sense of hope it gives us – and the feeling that we can make a difference.”

Jdr

F i dO

nO

r s

up

pO

rT

hope is a Cohn Family TraditionBack in 1971, JDRF was still a fledgling organization, and founder Lee Ducat was working tirelessly to raise money for research. To help plan a Gala for the new Philadelphia-based foundation, she turned to two friends – Norman and Suzanne Cohn – to chair the event. The Cohns had no personal connection to type 1 diabetes; they just wanted to help.

COhN family

20

gALA

Today, JDRF hosts more than 95 Galas nationwide – attracting over 44,000 people – each year. The Galas provide a fun, elegant evening filled with dinner, cocktails, entertainment, and silent and live auctions. Gala evenings are highlighted by JDRF’s signature Fund A Cure, a live auction which has raised more than $140 million for diabetes research since it began in 1994.

Each Gala has its own honoree(s) (an individual, couple, family, or business), who not only give generous support of their own,

but also bring in additional support from people they know. At the Gala, JDRF recognizes the honoree(s) – celebrating their efforts and the progress they’ve helped make toward better treatments and a cure.

We are pleased to recognize here the honorees who helped lead their chapters in raising more than $100,000 through the FY2010 Galas. Our thanks goes to these special supporters and to all the honorees, supporters, and volunteers who make JDRF Galas so successful and inspirational.

Started in communities around the country long ago, JDRF’s Gala program officially launched in FY2000. The program has raised over $450 million since its inception, with $52 million raised in FY2010 alone.

dO

nO

r s

up

pO

rT

i

Jdr

F

Advance Auto Parts Team Members, Customers & Vendor PartnersAdvance Auto PartsGreater Blue Ridge Chapter

Citlali & Fernando AguirreGreater Cincinnati Chapter

Amy & Jared AllenKansas City Chapter

William Danforth Metro-St. Louis/Greater Missouri Chapter

Richard & Karen DavisCapitol Chapter

Al de MolinaGMACCharlotte Chapter

Suzy Doherty, Managing Director & Sean Doherty, General CounselBain CapitalNew England/Bay State Chapter

Lee Ducat & Good Neighbor PharmacyDiabetes ShoppeEastern Pennsylvania/Delaware Chapter

John & Debbie EckFairfield County Chapter

Jay Fishman, Chairman & CEOThe Travelers Companies, Inc.North-Central Connecticut/Western Massachusetts Chapter

Founding FamiliesGreater Dallas Chapter

The Hendren Family (Eileen, Mike, Ruth & Charles Hendren)Triangle/Eastern North Carolina Chapter

Darren Jackson, CEO; Mike Norona, CFOAdvance Auto PartsMinnDakotas Chapter

Pitch & Cathie Johnson Asset ManagementGreater Bay Area Chapter

Gregory B. Jordan, Global Managing ParnterReed Smith, LLPWestern Pennsylvania Chapter

Sandra E. Peterson, Executive Vice PresidentBayer HealthCare, LLCNew York City Chapter

Nina & Mitchell Quaranta; Louise & Terrance GreggLos Angeles Chapter

John Reisman Jack Parker Corporation John CammettAerotermFlorida Suncoast Chapter

Arthur & Nancy RothNortheastern New York/Capital Region Chapter

Renee West, PresidentMandalay Bay Resort & CasinoNevada Chapter

Dr. & Mrs. Byron Williams (Living & Giving Awards)PricewaterhouseCoopersGeorgia Chapter

JDRF has more than

100 locations worldwide.

RESEARCH RESOURCES

RES

ULT

S

21

Jdr

F i dO

nO

r s

up

pO

rT

eight years ago, Fernando Aguirre, Chairman and CEO of Chiquita Brands International, Inc., was flying to Europe

with his wife, Citlali, and sons, Franco and Fabrizio. Suddenly, Fabrizio became violently ill. Being unable to do anything about it was traumatic, recalls Fernando. When the plane finally landed, the family rushed Fabrizio to a hospital, and it was there that they learned he had type 1 diabetes.

The Aguirres turned to friends and acquaintances to introduce them to other families affected by type 1 diabetes. It wasn’t long before they heard about JDRF. “We got high recommendations for JDRF, and that’s how we began to connect with the organization,” Fernando explains.

Yet to say that the Aguirres “connected” with JDRF is quite an understatement. They have been more than just generous donors and extremely involved volunteers. They are a family that has repeatedly given far more than what’s asked of them, while continuously thinking “outside the box” to come up with novel ways to benefit JDRF.

As Gala chairs in 2007 and honorees last May, the Aguirres are true champions for their Greater Cincinnati Chapter Gala. In addition to donating approximately $100,000 annually to the Gala alone, they put their hearts into it as well. During his acceptance speech at the chapter’s 2010 Cincinnatians of the Year Gala, Fernando spoke about the great research progress being made and the hope for a first-generation artificial pancreas in the near future. To help illustrate the potential of an artificial pancreas, he asked Fabrizio to do a “show-and-tell” of sorts – to lift his shirt and let the attendees see his continuous glucose monitor and insulin pump – both of which are key components of an artificial pancreas.

Bill Rice, the chapter’s Executive Director, says, “The Gala had incredible energy in the room, in large part due to the Aguirres.” Thanks significantly to the Aguirres’ involvement, the Gala was named best non-profit event in the Cincinnati community by the city’s Business Courier newspaper.

Fernando, who is chairing the Finance Committee on JDRF’s International Board of Directors for a second year and serving on the Executive Committee for a third year, has also brought his company into the cause. Chiquita hosted a golf tournament, the Chiquita Classic, on this year’s Nationwide Tour, with JDRF as one of the main beneficiaries.

Always paving new paths of generosity, the Aguirres have recruited close family friend Dhani Jones, a linebacker for the National Football League’s Cincinnati Bengals, to join them in a number of efforts benefitting JDRF. Fabrizio, now 18, collaborated with Dhani in designing a bow tie that initially sold for $57 (57 being Dhani’s jersey number), with all proceeds going to the chapter. Due to their enormous popularity, the bow ties originally produced – along with 75 extras made to meet the overwhelming demand – ended up being auctioned off for $100 each at the 2010 Gala. The Aguirres also donated a unique item to the Gala’s auction: an authentic Mexican dinner (cooked entirely by Citlali) for 20 people at the Aguirres’ home with Dhani as a guest – and including a promise that Dhani would visit the attendees’ kids at their schools. What anyone else would view as tremendous generosity Fernando views as common sense. As he says matter-of-factly: “The more you put in, the more you get out.”

Thanks significantly to the Aguirres’ involvement, the Gala was named best non-profit event in the Cincinnati community by the city’s Business Courier newspaper.

AguIRRe familyRedefining generosity: Aguirre Family goes Above and Beyond

22

CORpORATe pARTNeRs

hy-Vee helps support Research to Make Life “easier, healthier, and happier” for people with DiabetesHy-Vee

Hy-Vee, the employee-owned Midwestern grocery chain, says its aim is “Making lives easier, healthier, and happier.” One of the best examples of its delivery on that goal is its longstanding support of JDRF. Hy-Vee has been a steadfast JDRF supporter for 12 years now, contributing more than $10 million to research toward better treatments and a cure for people with type 1 diabetes.

How has Hy-Vee achieved so much? Each year, the

company holds a JDRF Sneaker Sales campaign with wrap-around events at many of its more than 230 grocery stores. Hy-Vee also sends a large group of employees, both current and retired, to participate in the Ride to Cure Diabetes program each year.

Hy-Vee is dedicated to serving the needs of local communities. In its eight-state region, Hy-Vee is very active at the local JDRF chapter level. The company’s employees serve on several chapter Boards, while forming teams for their local Walks and sponsoring/attending their local Galas. Moreover, through its in-kind donations of food, beverages, and giveaways for JDRF events, Hy-Vee helps JDRF to keep expenses at a minimum – meaning more dollars for research, and more potential for improving the lives of people with type 1 diabetes.

Corporations partner with us in a number of ways,

including Corporate Signature programs, the Walk

to Cure Diabetes, the Ride to Cure Diabetes, Galas,

retail promotions (namely paper Sneaker Sales),

golf events, and our Major Donor program.

Overall, Corporate contributions for FY2010 brought

in over $60 million to JDRF, which enables us to

continue finding and funding gaps in diabetes

research worldwide.

We deeply value our Corporate Partners and we are

pleased to recognize those partners that contribute

over $1 million annually and those honored at our

Annual Conference:

$2 Million Plus Partners

$1 Million Plus Partners

JDRF 2010 Annual Conference Award Recipients

Innovation Award: Novo Nordisk

Reaching New Heights Award: Build-A-Bear Workshop & Medtronic Diabetes

Chancellors’ Award: Roche Diabetes Care & Accu-Chek

Chairman’s Award: Ford Motor Company

President’s Award: Advance Auto Parts

JDRF Corporate Partners represent companies that truly understand and support our mission. We are proud to partner with many companies both nationally and internationally.

dO

nO

r s

up

pO

rT

i

Jdr

F

MAJOR DONORs & pARTNeRs

23

$3,000,000 and aboveAdvance Auto Parts

Ford Motor Company

The Leona M. & Harry B. Helmsley Charitable Trust

$1,000,000 - $2,999,999Hy-Vee, Inc.

Kellogg Family Foundation

Marshalls

Roche Diabetes Care

Walgreens

Lisa and Neil Wallack

$500,000 - $999,999Anonymous (1)

Estate of Jeanne Avegno

Delta Airlines, Inc.

Genentech, Inc.

Hille Foundation

Medtronic Diabetes

The O. Wayne Rollins Foundation

Estate of Lisl Schuhmann

Stop and Shop

Tops Markets, LLC

$250,000 - $499,999Mary and Dick Allen in Honor of Hannah

Cash America International, Inc.

Discover Financial Services

Tim and Lisa Fleet

The Fresh Market

Estate of Howard Halff

Judy and Walt Havenstein

Estate of Diane Hoag

Hurlbut-Johnson Charitable Trusts

Charles and Ann Johnson

Lipsig Family Foundation

McDonough Foundation

Novo Nordisk Foundation

Silpada Designs, LLC

The Collis/Warner Foundation, Inc.

$100,000 - $249,999Anonymous (6)

Advance Stores Company, Inc.

Allscripts

Bayer Diabetes Care

Becton Dickinson & Co.

Josh and Anita Bekenstein

The Benaroya Company

Bridget and Mike Bender

Fran and Bruce Bergman

Bloomingdale’s, Inc.

Jennifer Bolt

Boston’s Pizza

Mark, Valerie and Jason Brodsky

Buford Family Foundation

Build-A-Bear Workshop Foundation

Estate of Meade and Herbert Bynum

Carolina Restaurant Group

Casey’s General Store

Mr. Albert Chan

Cisco Systems, Inc.

Clear Channel Outdoor

The Coca-Cola Foundation

The Cohn Family Foundation

Mr. and Mrs. Matthew Cohn

Community Health Charities of Nebraska

Estate of Charles M. Conlon

The Cooper-Siegel Family Foundation

Cordeck’s Cruise for a Cure

Cordick Sales

Karen and Richard Davis

Al and Donna de Molina

Dr Pepper Snapple Group

Edward Jones

Ericsson

The Fine Family – Team Brotherly Love

Ashley and Michael Fisher

Ford KTP Cares

FOX 25

Larry and Charlotte Franklin

The James A. Gammon Charitable Foundation

GoDaddy.com

The Gregory Fund

Estate of Arthur Guarino

Harman Management Corporation

Karen and Cliff Harris

Harry S. Moss Heart Trust

Holmes Murphy

The Howard Family Foundation

Insulet Corporation

Solomon Jackson, Jr.

Jensen Charitable Lead Annuity Trust

Ron Jensen Charitable Lead Annuity Trust

Stacey and Dave Johnson

Jonas Brothers’ Change for the Children Foundation

Don and Donna Kelleher

Kirkland & Ellis, LLP

In Honor of Krista Klopp

Kohl’s Department Store

The Komar Family

John and Connie Kurkowski Family

Lakeside Industries

JDRF expresses its deep appreciation to the friends and partners who have so generously invested in our core programs. The people, corporations, and organizations listed below helped advance research toward better treatments and a cure by making an outright gift or pledge of $10,000 or more in FY2010.

Jdr

F i dO

nO

r s

up

pO

rT

JDRF has received an

“A” rating from the American Institute

of Philanthropy for 11 straight

years.

RES

EAR


Lasseter Family Foundation

Jonathan and Jeannie Lavine

The Lehto/Virga Family

LifeScan, Inc.

Eli Lilly and Company

The Lincy Foundation

Estate of Elmer Livingston

The Karen and Herbert Lotman Foundation

Boston Marriott Copely Place

The Meyer Charitable Foundation

Nationwide Foundation

Novo Nordisk

Michelle Griffin and Thomas Parker

Mr. and Mrs. Richard C. Patton

Pella, Inc.

Pioneer

QUALCOMM Incorporated

Quick Chek Food Stores

Republic Finance

The Partners of Ropes & Gray, LLC

Estate of Brenda Rudnak

Russell Stover Candies

Sage Hospitality Res.

Sanford Health

Janet and Flip Short Family Charitable Fund

Anonymous - In Memory of Carolyn H. Taylor

Tetco

Texans Credit Union

Texas Instruments

Travelers Foundation

Glen and Trish Tullman

Turner Broadcasting System, Inc.

Eve and James Tyree

USA Drug Stores

Ms. Hilary Valentine and Mr. Don Listwin

Virginia Mason Medical Center

Vivian and Louis Vance

Wawa, Inc.

Sharyl and John Weber

$75,000 - $99,999Anonymous (1)

Carolyn and Kenneth Aldridge

Aldridge Electric

BP America

Mr. and Mrs. John Cammett

Marci Eisenstein and John Treece

Gilbert and Jacqueline R. Fern Foundation

George Polli Foundation

Gordmans, Inc.

Estate of Joanne Gorman In Memory of Cynthia Ann Hawkins

Patty and Kenneth Halverson

Mr. and Mrs. William Fred Hagans

Hess Corporation

Estate of Bernard Jaffee

Mr. and Mrs. Donald Jones, Jr.

D. Scott and Pamela Kroh

Kum & Go

Lunds & Byerlys

Monica Maliskas

Medtronic Foundation

Amy and Alan Meltzer

The Neilan Foundation

Old Orchard

Melitta S. Pick Charitable Trust

PPD

RR Donnelley

Arthur and Nancy Roth

Pamela and William Sagan

David and Janelle Shaffer

Mr. and Mrs. Morton Silver

The TJX Foundation, Inc.

Estate of Freda Watts

Yum Brands, Inc.

$50,000 - $74,999Anonymous (3)

AAR Corp.

Abbott Diabetes Care

Aimbridge Hospitality

Alpine Children’s Charity

Mr. and Mrs. Neal Allen

Estate of Robert D. Allen

Estate of Helene Alley In Memory of Theodore Whitlock and Theodore Whitlock, Jr.

Steve and Lisa Altman

Amgen

The James Annenberg La Vea Charitable Foundation

Aon Risk Services Northeast, Inc.

Asset Management Company

Bank of America

Lynda and Chris Barnes

Ann and Sam Barshop, Colleen and Bruce Barshop and Jamie Barshop

The Barstein Family via The Birmingham Jewish Foundation’s JDRF/Israel Fund

BB&T

Michael and Carolyn Bealmear

Big Y

Blackbird Technologies, Inc.

BLMF

Blue Cross Blue Shield of Georgia

BP Lubricants USA, Inc.

Roy and Vanessa Carroll

Dr. Carol Cheney and Dr. Josh Bardin

Chubb Group of Insurance Companies

CIGNA

Coca-Cola Enterprises

Elsie T. & Josephine Colombo Charitable Trust

Community Health Charities of Illinois

Robert Compton

Mr. William R. Conley, Jr.

Cravath, Swaine & Moore, LLP

CSX Transportation and Friends

Cushman & Wakefield

Henry D’Auria

Sean and Suzanne Doherty

Arnold Donald and Family

R.L. Donald, Jr. Family Trust

Ed Miniat, Inc.

Sandy and Paul Edgerley

Ernest Lieblich Foundation

Christine and Larry Fee

Mr. and Mrs. Alan Fisher

Ford Sharonville

Laura L. and Robert T. Fraley

The Franke Family

Estate of George T. Gorman In Memory of George and Pearl Gorman

Granite Properties

Guilford Foundation

Rita Haddow

Harris Teeter, Inc.

The Haun Trust

H-E-B

Edward Heil

Michael and Eileen Hendren

High Points Auto Insurance

Hopkins Capital Group II, LLC

Howard Industries, Inc.

Jansen Family Foundation

24

MaJOr dOnOrs & parTners continuedd

On

Or

su

pp

Or

T i

Jd

rF

285 million people worldwide have

diabetes; by 2030, it’s predicted that

435 million will have the disease.

RESEARCH RESOURCES

RES

ULT

S

25

w hen Bob and Joan Lipsig’s three-year-

old daughter, Lynn, was diagnosed with type 1 diabetes nearly 40 years ago, her future looked bleak. They were told her life expectancy would be only about 30 years.

After looking at several organizations for support, they learned about a new one called the Juvenile Diabetes Foundation. They were drawn to this newcomer, because unlike any of the others, it was actually searching for a cure. The Lipsigs decided to connect with the foundation’s chapter in Chicago – and that was the beginning of a long and fruitful partnership.

Bob says it was JDRF’s professionalism that convinced them to dedicate their time and money to the organization.

“Obviously for our daughter, we needed to do whatever we could to make her situation better,” he says. “But I think what probably swayed me the most, in terms of getting involved, was the analytical business approach that JDRF took toward the research.”

Joan says she threw herself into volunteering for JDRF once Lynn graduated from high school and left for college. She and Bob served on the chapter’s Board, doing whatever was asked of them. “The chapter had a great cadre of people, and it was almost a family kind of a mission,” Bob says. “We shared each other’s traumas and trials and tribulations.”

By the early 1990s, the family’s resources from their business – manufacturing and importing sporting goods and children’s licensed products – had grown to the point where they could begin making consistent, if not “significant” donations to JDRF, Joan says.

“We’re not in that million-dollar class of people; we’re just those middle-class people who just keep trodding along,” she says. “It takes all of us to do our job. We’re all important in our own way; we all contribute and do what we can.”

In addition to their own generosity, they also helped JDRF raise funds from others. Bob signed on as a Board member for

JDRF’s first international capital campaign. At the time, JDRF was pioneering interdisciplinary research, bringing together a variety of research specialties as the best chance of finding a cure.

“I think that really got my attention,” Bob says, “because as opposed to just throwing a lot of money at certainly a worthwhile cause, we were

approaching it from a very systematic way, evaluating our investment and constantly insisting that the recipients of our funds were made to account for it.”

The Lipsigs definitely feel that their investment has paid off. Lynn, now 41, is a consultant with a midsize consulting group in Chicago (and herself a former Board member of the Illinois Chapter). Bob and Joan credit research advances with helping their daughter remain healthy well past the life expectancy originally forecast for her. For example, they say the landmark Diabetes Control and Complications Trial, funded in part by JDRF, convinced Lynn to achieve tight blood glucose control to reduce her risk for complications. They also point to advances in retinal surgery as having saved Lynn’s eyesight.

They are undaunted by the fact that the cure has not yet been found. “We’re not bitter we haven’t cured it; we’re just thankful our daughter Lynn has been able to live as quality a life as she has, with a good hope of living a long and normal life in later years,” Bob says. “That, to me, is critical.”

Says Joan, “We really feel that there’s a chance out there. You can’t give up; science takes time. When Lynn was diagnosed we were doing urine test strips, which were about as accurate as nothing! So think of that, the progress that’s been made.”

Nearly Four Decades of supporting JDRFL I psIg family

Their message to other families is to focus on the advances that have already been made, while continuing to consistently support research. They have not given up hope for a cure.

Jdr

F i dO

nO

r s

up

pO

rT

Johnson & Johnson

Johnson Controls

Pitch and Cathie Johnson

JP Morgan Chase

Joanne Kagle

Mr. and Mrs. John Kampfe

Dusty Elias Kirk and William R. Caroselli

Barbara Kouris

Estate of Dorothy F. Krause

Estate of Erwin Levy Kremen

Kroger

Kenneth and Jennifer Kroner

Sandra L. Kurtzig Foundation

Ladd and Hogue Trust

Pat and Frank Liberto

LIUNA

Madden Charities, Inc.

Jade and Mark Matlock

Phyllis McGovern

Estate of Ruth McLaughlin

Matthew Meister

Shannon and Bart Millard

Monsanto

Mr. and Mrs. Leo Mullin

NBC Universal

Debbie and Stephen Newman, M.D.

Myron Noble

In Memory of Kevin Christopher Nolan

Nordstrom

Northwestern Mutual Financial Network

George L. Ohrstrom, Jr. Foundation

Orkin

Ms. Jane Parker

Permatex, Inc.

Plaza Marketing Associates, Inc.

The PNC Financial Services Group

Point of Hope, a Deron Williams Foundation

Estate of Jean Pond

Thomas and Stella Press

Steve and Cindy Rasmussen

The Reynolds Company

Estate of Earl and Laurel Rogers

Marlene and Bruce Saltzberg

Renee and Robert Samuels

Saturday Club of Wayne, PA

Denise and Marc Schmittlein

Robert and Candi Selig

Sequent Energy

Sonora Quest Laboratories

Estate of Carol Sorensen

Standard Motor Products

Michael and Debora Sullivan

Estate of Bettie W. Sumara

Swat-Fame, Inc.

Taylor Family Foundation

Tesoro Corporation

Thinkway Toys

UnitedHealthcare

Richard and Marie Unnerstall

University of Pittsburgh Medical Center

Utah Angels

Vintage Hollywood

Wells Fargo

Williams Trading, LLC

The Woodbury Foundation

$25,000 - $49,999Anonymous (7)

3M Corporation

7UP

Abby’s Friends Foundation

Abbott Fund

AC Delco

Accenture, LLP

Diane Adams

Amy and Micah Adams

Aetna, Inc.

AGL Resources

Airtex Products, LP

Akin Gump Strauss Hauer & Feld, LLP

Albertsons

Alcoa Foundation

Amy and Jared Allen

Allstate Giving Campaign

Ally Bank

Alpine-Litho Graphics

American Legion Child Welfare Foundation, Inc.

Amylin Pharmaceuticals, Inc.

Michelle and Richard Anderson, M.D.

Anheuser-Busch Companies

The Annenberg Foundation

Anthem Blue Cross

Arch City Theater Troupe

Mr. and Mrs. Jeff Arnold

AT&T

Charles F. Avery

B&D Industries, Inc.

Cathy and Rick Baier

Bain Capital Children’s Charity

Baker Hughes

Bank of New York Mellon Asset Servicing

Barbara Davis Center for Childhood Diabetes

Barclay’s Capital

Ann K. and G. Kenneth Baum

BBB Industries

BBDO

BBH

BD Technologies

Belk, Inc.

Toni and Steve Berlinger

Junior Beta Clubs of Louisiana

BKD Foundation

Blank Children’s Hospital

Blue Cross Blue Shield of Mississippi

Bluegreen Corporation

Christopher Bolt

Bombardier Aerospace Corp.

Bon Secours Richmond Health System

Bosch

Bosch (Purolator)

Bill and Ute Bowes

Kara and Kevin Boyle

Tony and Amy Briney

Brinton Eaton

The Brockriede Family

Kate and Peter Brown

Terry and Cindy Brown

BTIG, LLC

Mr. and Mrs. J. Mahlon Buck, Jr.

Betty Burnham

Edward L. Calcaterra

Mitchell and Cindy Caplan

Francois and Laura Cardinal

Carl M. Freeman Foundation

Margo and John Catsimatidis

Cellino & Barnes

Cenegenics Medical Institute

Cereal Food Processors, Inc.

The Rhoda and David Chase Family Foundation

Chevron

Bill and Kim Chisholm

26


On

Or

su

pp

Or

T i

Jd

rF

The Ride to Cure Diabetes

in Killington, VT raised $1.4 million in FY2010 — more than any Ride in

JDRF history.

RESEARCH RESOURCES

RES

ULT

S

27

Cia Centro Inspection Agency

Emory T. Clark Family Charitable Foundation

Clark Construction Group, LLC

Brett and Karen Coleman Foundation

Cooley Godward Kronish, LLP

E.L. Cord Foundation

Laura and Kelly Crain

Credit Suisse

Crowley Automotive Group

Mark Curry

CVS Caremark

Dade County Federal Credit Union

D’Agostino Supermarkets, Inc.

Danaher Tool Group

The Dash to Cure Diabetes, Inc.

DCP Midstream

Cathy and Alex Debelak

Arlo and Barbara DeKraai

Denso Sales

Diabetes Shoppe

DIRECTV, Inc.

Dobbs Tire & Auto Centers

Barbara and Peter Dyson

Norman Eaker

East Penn Manufacturing

John and Debbie Eck

Bill and Barbara Edwards

Electronic Tax Center

EMWIGA Foundation

Energizer Holdings, Inc.

Kim and Peter Enns

Entergy

Brady Exber

Exelon Corporation

Cindy and Robert Fairchild

Federal Home Loan Bank of Atlanta

Federal Mogul

Judy and Richard Feldstein

Domenic and Molly Ferrante

Fidelity Charitable Gift Fund

Fifty 50 Pharmacy

Fifty 50 Medical Devices, LLC

First Community Bank

First National Bank

Mark and Lisa Fischer-Colbrie

Randy and Jay Fishman

Flextronics

Thomas J. Fogarty, M.D.

Harrison Ford and Callista

Flockhart

The Henry Ford II Fund

Ford Louisville Assembly Plant

Franklin Templeton Investments

Mr. and Mrs. Gregg Freishtat

Patricia and Steven Gabbe

Barbara M. Gasser

GEICO

Genpact

Joanne Gimbel

Glen Cove PBA

David Glick

GMB North America, Inc.

Mr. and Mrs. Seth Godin

Goldberg, Kohn, Bell, Black, Rosenbloom & Moritz, LTD

Beth Kreeley Goldstein and Dennis Goldstein

Good Times Burgers

Eunice and Douglas Goodan

Mike and Becky Goss

Estates of John R. and Elaine B. Grady In the Name of Timothy Richard Grady

Grant Thornton, LLP

The Graves Foundation

SL Green Realty

Greenberg Traurig, LLP

Terry and Louise Gregg

David P. and Toni Halle, Jr.

Donald and Nedra Hansen

The Stephen P. Hanson Family Foundation

H. Edward and Ellen Hanway

Alice and Raymond Hartke

Brad and Kim Hayes

Hayes + Associates

HealthTrust Purchasing Group Tees Up for Kids

Henry Schein, Inc.

Highmark Blue Cross Blue Shield

Kathy and Jim Hipps

Hoffman Car Wash and Jiffy Lube

Tim Hoiles and Lorie Mondo

Honeywell

Hope For A Cure Guild

Sam and Anne Hummel

Imagine a Cure

Indianapolis Marriott Downtown

International Association of Heat and Frost Insulators & Allied Workers

Intricon Corporation

Jacks Family Restaurants, Inc.

Mr. and Mrs. James Jacobson

JDRF North Iowa Volunteers

Jewelers Charity Fund For Children

Robert Wood Johnson Foundation

Karen and Jeffrey Jordan

Gregory and Ellen Jordan

Kaiser Permanente

Edward and Irene Kaplan

Michael Keaton

Bonnie and Jerry Kelly

Jdr

F i dO

nO

r s

up

pO

rT

giving You Can Cuddle up To Build-A-Bear Workshop

Last year, Build-A-Bear Workshop decided to turn its special expertise toward a new kind of building project: namely, building support for JDRF among its guests.

During its annual retail campaign supporting JDRF, Build-A-Bear Workshop initiated a point of sale donation collection program in all U.S. stores, requesting a $1 donation from every customer at the time of checkout. At its Canadian stores, Build-A-Bear offered the company’s signature purple satin hearts to customers for $1.

Customers responded to these innovations with great enthusiasm, enabling the Build-A-Bear Workshop Foundation to deliver almost $209,000 to JDRF in 2009 – a nearly 575 percent increase over the previous year’s total!

Build-A-Bear Workshop has been a JDRF corporate supporter since 2003, generating more than $400,000 for diabetes research in that time. The partnership stretches from local to national levels: the company hosts local events in support of JDRF at its World Bearquarters in St. Louis, and holds its nationwide retail fundraising campaign each November in conjunction with National Diabetes Awareness Month.

28

MaJOr dOnOrs & parTners continued

How has Steve Winer made a difference in the lives of thousands of people with type 1 diabetes?

He helped create the Online Diabetes Support Team, a volunteer group that answers all kinds of questions about the disease from people all over the world. In the process, he helped establish a role for outreach at JDRF.

Q

A

The story begins back in 1997. At that time, the Internet was still

a relatively new phenomenon for most people. But not for Steve, who was then working for a small Internet service provider on Long Island and well-versed in all things Web.

When Steve’s daughter, Allie, was diagnosed with type 1 diabetes that year at the age of 11, Steve used his Internet savvy to do some research online, and ended up connecting with other parents through message boards and chat rooms – including Ardy Johnson of Seattle, whose son had type 1 diabetes. Steve learned about JDRF and connected with his local Long Island Chapter.

Soon thereafter, JDRF’s national office asked Steve to share his expertise by joining its volunteer-led Information Technology Committee. At the time, JDRF’s website was “young and incomplete,” and committee members were grappling with questions like “what do we need to do with this

Internet stuff?” as Steve recalls. He and others saw great potential to using technology to support the JDRF mission.

Steve and Ardy championed the idea of establishing JDRF as the “go-to place” for people needing information and advice; they decided to create an “online support team” of volunteers – people who had “been there, done that,” as Steve puts it. The team would provide crucial support by answering people’s questions – submitted via the JDRF website – about living with type 1 diabetes.

With Steve and Ardy spearheading the effort, the “Online Diabetes Support Team” (ODST) was launched in 2003 on Christmas Eve, with three moderators to read through questions and forward them to the 10 people who had signed on as “responders.”

ODST very quickly outgrew the Excel spreadsheets that were originally used to keep track of its operations. Today, ODST receives 200-300 requests a month – 40 percent of them relating to diagnoses within the past year. Earlier this year, the program celebrated a huge milestone when it received its 20,000th question.

Today, there are 10 moderators – including Steve and Ardy – and at any given time, up to 100 responders, one of whom is Steve’s daughter, Allie, now 24.

“I never imagined it would grow like this; I really never did,” Steve says. “It’s really pretty cool. It was all done totally grassroots, all by the seat of our pants, at no cost to JDRF.”

The “one-to-one targeted connection” is what makes ODST particularly special, Steve says. Moderators try to forward each question to a responder who has experience with the issue being described. For example, if a teen wants advice about the best way to keep an insulin pump hidden under her prom dress, the moderator will identify a responder who has tackled that herself. If a mother is concerned that type 1 diabetes will keep her son from being able to play soccer, the moderator seeks a responder who has been there, too.

The site gives no medical or legal advice. Rather, ODST is “just people whose lives have been impacted by type 1, giving advice about day-to-day living with type 1 diabetes,” Steve says.

The ultimate goal is to hook questioners up to their local chapters – so that they can then connect with other type 1 families in their communities and also with other JDRF programs that can help them live well with type 1 diabetes.

Beyond helping people, ODST has also had a big impact on JDRF as an organization, Steve says. “We now see outreach as part of what we should be doing,” he says. “ODST has helped change the culture of JDRF.”

sTeVe WINeRConnecting for a Cause: The story of ODsT

dO

nO

r s

up

pO

rT

i

Jdr

F

Bonnie and Lawrence Kivel

Tony and Sheryl Klein

Mr. Maury Klumok

The Koch Foundation

Steve and Marilyn Kraft

Katherine Kupferer

Latham & Watkins, LLP

Judy and T. Scott Leisher

Christopher and Rebecca Lien

The Lincoln Electric Company

Donna Longo

Gloria Loring via Are You Smarter Productions, Inc.

Shelley and Douglas Lowenstein

Edward and Kathy Ludwig

Lynyrd Skynrd

Macy’s Foundation

Major League Baseball Players Alumni

Al and Claude Mann

Linda and Aaron Martenson

Uzal and C. Jun Martz

Marvin L. Baker Family Foundation

Mashantucket Pequot Tribal Nation

Susan and James Maslowski, Sr.

Stuart and Flora Mason

Estate of Earl V. Mason In the Name of Alice E. Mason

Maxon Precision Motors, Inc.

Mazda North American Operations

Sarah and Bryan Mazlish

The H.F. McCarty, Jr. Family Foundation

Mr. and Mrs. James McDonald

McKesson Foundation, Inc.

McKinney-Geib Foundation

Kim Medley

Menasha Foundation

Mesirow Financial

Stanley Meyers

Ron and Diane Miller

Mr. and Mrs. Eugene C. Miller, III

Millstadt Optimist Club

Beth and J. Barry Mitchell

Estate of Marian L. Moore

Morgan Stanley

Mother Tried Foundation

Motorcar Parts of America (MPA)

Leslie Mulholland

Mure & Carone P.C.

Harvey E. Najim Family Foundation

James & Sally Nation Foundation

Barbara and Thomas Neal

The Neilsen Company

Daryl and David Nelms

New Hanover Regional Medical Center

NJ-Sim Foundation, Inc.

Norjana Charitable Foundation

Old World Industries

Omaha Steaks

O’Neal Steel

Optima Fund Management, LLC

Mike and Trina Overlock

Dr. Graydon and Shelley Page

Palmetto Restaurant Group, LLC

Norma Parker

John J. and Joan M. Pasteris

Loretta and Douglas Patterson

John and Cindy Paul

Pavarini McGovern, LLC

PCB Piezotronics

peermusic

Penn Traffic Company

PepsiCo

Perot Foundation

Marilyn and Phil Perricone

Robert and Jill Petcove

Jeff Petro

Peyton Manning Children’s Hospital at St. Vincent

Piccadilly Restaurants

PIMCO Foundation

Roy and Yvonne Polatchek

Melinda and Richard Poulton

The Price Family Foundation, Inc.

PricewaterhouseCoopers

Publicis

Mitchell and Nina Quaranta

Stephen and Anne Rader

Ron and Barbara Rapaport

Gary and Anita Rathburn

Chris and Sarah Redlich

Mr. and Mrs. Jack Reed, Jr.

Reed Smith, LLP

Melissa and Thomas Reedy

Mr. John Reisman

Mr. and Mrs. Robert and Bobbi Reitzes

REMY

Donald and Nancy Resnick

Michael and Joannie Rich

Mrs. Debby Robbins

Robert W. Johnson, IV Charitable Trust

Robindale Energy Services, Inc.

C.H. Robinson

Linda Benge and Paul Robshaw

Lisenne Rockefeller

Julie and Len Rodman

Kathy and William Roe

James and Sharon Rohr

Mr. and Mrs. Scott C. Rolles

The Ron Santo Golf Experience

Kim and David Roosevelt

Harriet Ross

Toby and Michael Rozen

Saipem America

Jack and Anita Saltz Foundation

Sanofi-Aventis

Thomas and Mary Pat Santel

Margaret and Robert Schafer

Estate of Amelia Schmitz

Jennifer Schneider and Dain DeGroff

Shakopee Mdewakanton Sioux Community

Alan and Sandra Silvestri

Ms. Sydney Simons

Arnold J. Simonsen Foundation

K.P. Singh

Smoker Friendly International, LLC

Sony Electronics, Inc.

Estate of Margaret Sorensen

Mr. and Mrs. Joseph Spano

Starcom MediaVest Group

STERIS Corporation

Susan and Rick Sterling

Barry and Mimi Sternlicht

Carol Stillwell, Stillwell-Hansen, Inc.

Sun Products

Kris and Greg Swetnam

Tata Consultancy Services

Telvent DTN

The Thomas Foundation

Joan and Byron Thompson

Sharlyn and Wade Threadgill

Title Guaranty of Hawaii

Touchstone Communities

Tower Loan

Trozzolo Communications Group

TRICO

University of California

UPS

29

www.jdrf.org/diabetessupport

Jdr

F i dO

nO

r s

up

pO

rT

JDRF’s Online Diabetes Support Team has handled more than 20,000

requests from people with a type 1 diabetes

connection seeking support.

RES

EAR


30


Valero Energy Foundation

Bruce Vaughan

Vistakon, a Johnson & Johnson Company

Wachovia

Wachtell, Lipton, Rozen & Katz

The Walbridge Fund, LTD

Walmart Foundation

Teresa and Thomas Walsh

Jim and Stacey Weddle

Weil, Gotshal & Manages, LLP

Gail and Charles Welliver

WellMed

Western Refining Co.

Fred and Elizabeth Wiese

Willbros

Robin Williams

Dr. and Mrs. Byron Williams

Timothy and Christi Windler and Family

Richard S. Worthington

Workers Compensation Fund

Worth Harley-Davidson North, Inc.

Sharon and David Wright, III

Ellen and Stavely Wright

Monica and Robert Yolles

Robert and Leslie Zemeckis

$10,000 - $24,999Anonymous (16)

1st Bank

432 Park South Realty Co.

ABB Foundation

Karen Abbruzzese

Dr. and Mrs. Marshall Abes

Lisa and Michael Absatz

Absolute Pharmacy, Inc./Avalon Foodservice, Inc.

Jeff and Wendy Adams

Mr. and Mrs. John S. Adams, Jr.

AE Petsche Company

Aegon Transamerica Foundation

AEP

Aetna Foundation

AFLAC

Vikram Agrawal

Ms. Jane Aklestad

Akron Children’s Hospital

Alabama Power Foundation, Inc.

Alberto Culver

Jenna Alexander

All Access Apparel, Inc.

Allegacy Federal Credit Union

Allegheny Technologies

Jon and Mary Beth Allegretti

The Allergan Foundation

Allergan, Inc.

The Allstate Foundation

Dean and Shelby Alms

Alro Steel Foundation, Inc.

Alston + Bird, LLP

AMCI Capitol

Amedisys

American Airlines

American Express Charitable Fund

American Express Travel Related Services

American General Life and Accident Insurance Company

Ametek

Amherst Securities Group

Jenny and Gil Amoroso

Mary and Tom Anderson

Mrs. Carleen Andrews

Christine and John Andrie

Angel MedFlight

Animas

Julie Ann and Brian Annulis

Robin and Darrin Antrim

Appel Open for JDRF

Mr. Bernard Aptaker

Allen and Helene Apter

Milton Arbitrage Partners, LLC

Arch Capital Services

Archon Corporation

Arkansas Blue Cross and Blue Shield

Lisa and Jeffrey Aronin

Annabel Galva-Arthur and Jason Arthur

Dr. and Mrs. Todd Asarch

Ascent Media Group, LLC

John and Rosalind Ashkar

ASICS

Associated Packaging, Inc.

Aultman Hospital

Rick Austin

AVID

AVM

BAE Systems

BAE Systems Norfolk Ship Repair

Baggett Transportation Co.

Mr. and Mrs. Robert Bailey

Robert W. Baird

Baker Tilly

Jennifer and Don Baldridge

Susan and Jim Baldwin

Bank of America/Merill Lynch

BankPlus

Bantle & Walker

Baptist Health South Florida

Dr. and Mrs. Michael Barber

C.R. Bard Foundation, Inc.

John Bardis

Barnes Charitable Foundation

Earlene and Bob Barnes

Barona Band of Mission Indians

Irving Barr

Robert A.J. Barry

Jennifer and John Basham

Richard Bassuk

Coca Cola Bottling of Baton Rouge

Patrick Baumgarten

Baylor University Medical Center

BBVA Compass Bank

BD Medical

Edwin Beachler

Jennifer and John Beard

Elizabeth Ann Beck Foundation

The John and Frances Beck Family Foundation

Becker Family Foundation

Robert and Kellie Belk

Dr. William F. Bell

Bender Foundation

Brian Benjet and Kim Emmons-Benjet

Mignon and Les Bentley

Brent Berge

Berkeley College

W R Berkley Corporation Charitable Foundation

James and Diane Berliner

Robert and June Berliner

Bernstein Management Corp. (Joshua Bernstein)

Ray Berry

Tom and Lise Bessant

Susan and Stan Bever

Mr. and Mrs. Tom Bibb

Bingham McCutchen

W. Bisso, IV

Black, Starr & Frost

Greg Blackmon

Mr. and Mrs. Thomas Blackmon

dO

nO

r s

up

pO

rT

i

Jdr

F

Every year, more than 30,000

new cases of type 1 diabetes

are diagnosed in children and

adults.

RESEARCH RESOURCES

RES

ULT

S

Frank and Sandra Blanchfield

Mr. and Mrs. Gary Has

The Bill Blass Foundation

Marv and Toby Blecker

Joann Blehi

Bloomberg Financial

Bloomington Lions

Blue Bird Auxilliary

Blue Cross Blue Shield of Alabama

Blue Cross Blue Shield of Arizona

Blue Cross Blue Shield of New Mexico

Blue Cross Blue Shield of North Carolina

Blue Shield of California

Blue Slate Solutions, LLC

Blue Package Delivery

BNY Mellon

The Boeing Company

Mr. and Mrs. Michael and Stacey Bonagura

Judy Bond

Bonner Family Private Foundation, Inc.

Shannon and Rik Bonness

Daniel and Deborah Booker

Borger Management

Boston Scientific Corporation

Mr. and Mrs. Grant Boyd

BP Activities Association

Elizabeth and Charles Bracken

Dan and Annette Bradbury

Judy and Ray Brandt

Brasfield & Gorrie

David and Gail Braswell

Cheryl and Bob Brecht

Brencourt Advisors, LLC

Mr. and Mrs. Gregory Brenneman

Warren and Elaine Breslow

Mr. and Mrs. Tracy Brettmann

Anastasia and Nicholas Brien

Mr. and Mrs. Chris Broders

Greg Brody

Bill and Betty Brooks

Brooks Sports, Inc.

Brothers Air & Plumbing

Mr. and Mrs. Bob Brown

Brown & Tarantino

Tammy and Bruce Broyles

Brubaker Family Foundation

Bruce Bergman Foundation

Mary Lou and Stewart Bruce

Mr. and Mrs. Mike Bruns

Ms. Kirsten Buchanan

Bucyrus Foundation

Gary and Loraine Budke

The Bugas Fund

Bulgari Corporation of America

Mary Elizabeth and Jeffrey Bunzel

David and Barbara Burstin

Burstin, Burstin & Frantz

Business Support Group For Platt College

C.W. Butler

Lynn and Chad Buxton

Byrne Family Foundation

C.H. Guenther & Son, Inc.

Cablevision Systems Corp.

Cactus Software

Becky Cage

Steve Cage

Gloria and Louis Cairo

Cajun Cruisers

Jo Ann and Peter Calvanico

The Capital Group Companies Charitable Foundation

Karen and Peter Capuciati

Car Program, LLC

Cardinal Health

Cardone

Alexis and Scott Carmer

Caroselli, Beachler, McTiernan & Conboy

The Carriero Family

Evelyn C. Carter Foundation, Corp.

Suzanne and Michael Carusillo

The Thomas and Agnes Carvel Foundation

Mary Kate and Rob Cary

Karen and James Case

Casey’s Charities, Inc.

Mr. and Mrs. Andrew Cash

Mr. and Mrs. Jerry Cash

Catholic Archdiocese of New Orleans

Catholic Healthcare West

Mike Cavallo

CB Richard Ellis

The Cementworks, LLC

Centennial Bank

CenterPoint Energy

Centre Partners

Chadbourne & Parke, LLC

Champagne

Llee and Jill Chapman

Chapman Family Foundation

Charter Business

Chevron Products Company

Chevron Oak Point

City of Chicago

Chicago Cubs

Chicago Title Insurance Company

Children’s Hospital of Los Angeles

Children’s Hospital of Pittsburgh of UPMC

The Children’s Regional Hospital at Cooper

Mrs. Celeste F. Childs

Richard and Barb Christensen

Dianne Christensen

Chubb & Son Incorporated

Citigroup, Inc.

City National Bank

Toni and Tim Clark

Classic Industries, Inc.

Mrs. Mary Clay

Clean Energy

Clear Channel Communications, Inc.

The Clingen Foundation

Martin Cobb

The Coca-Cola Company

Mr. and Mrs. Fielding Cocke

Ron and Susie Codd

Coffee Serv

Neil and Marcy Cohen

Sandra and Sheldon Cohen

Rhonda and Russell Cohen

Lisa and Gary Coleman

Steve Collins and Carmen Gantt

Joe and Laura Colmery

Comcast

Community Hospital of the Monterey Peninsula

Community Foundation of North Texas

Community Foundation of Tampa Bay

Community Surgical Supply

Stephen Conley

Stephanie and John Connaughton

Marsha and Michael Connellan

Lisa and Ken Conway

Todd and Beth Cook

Mr. Richard Cooper

Cops Running for Charity

31

Jdr

F i dO

nO

r s

up

pO

rT

www.jdrf.org/adults

JDRF’s Adult Type 1 Toolkit

has been downloaded by

nearly 4,000 people.

RES

EAR


Cordray Foundation

Corn Products Specialty Ingredients

Missy and Chris Costello

Covance

Coventry Health Care

Faye L. and William L. Cowden Charitable Foundation

Amy Coyer

Carol and Denis Crawford

Creditors Collection Service

Lynne and Richard Creed

John and Karen Creelman

Kitty and Tom Crisham

CTS Corporation

Dr. Vincent and Mrs. Cheryl Culotta

Debbie and Guy Culpepper

CUNA Mutual Group

Joanne and Fred Cunha

Alice and Craig Cuvelier

Elinor M. Cuvelier Trust

Cy Pres Class Action Settlement

Daedalus Foundation

Lauren Daitch

Stacey and Don Dale

John and Georgia DallePezze

Dr. William H. Danforth

Dr. and Mrs. Howard Darvin

Data-Mail, Inc.

David Winans GMAC Real Estate

Mark and Nancy Davis

DaVita

Dayco Corporation

The Dayton Foundation

Dean Health Plan

Michael Dearing

Dr. and Mrs. William Deaton

Thomas and Lorraine Deeney

Elizabeth and Seth Deleery

Dell, Inc.

Delta Dental Plan

Deltic Timber Corporation

Dematic Corp.

Estate of Paul Deniger

Desert Diamond Casino

Leanne DeShong and James Conlon

Michael DeSimone and Dr. Susan Hughes

Steve and Nanette DeTurk

Mr. and Mrs. Richard DeVos

DexCom, Inc.

Diamond Management & Technology Consultants, Inc.

Dick’s Sporting Goods

Louis DiNardo and Julie Stein

Dawn and Sid Dinsdale

Mr. and Mrs. Kane Ditto

Estate of Richard Nason Doheny

Donatelle Plastics

Estate of John and Mary Donecker

Doner Advertising

Barbara Donnell and Scott Markus

Donovan Wright Advisors, LLC

Dopkins & Co.

Yale and Sherrie Dorfman

Rans and Margaret Douglas

Douglas J. Aveda Institute

Dove Family Foundation

Downey & Company

Diana and Robert Doyle

Dreisenszun Family Foundation

Mr. and Mrs. James Drone

Bill and Barb Drotar

Drury Inns, Inc.

Lee Ducat

Dunkin Donuts

Duplicolor Products Company, Inc.

Eunice L. Dwan 1991 Irrevocable Trust

Pat and John Dyer

Christopher and Bijen Dyrek

Eagle Materials, Inc.

Mr. and Mrs. Jay Eastman

Mr. and Mrs. John Eastman

Ms. Louise Eastman-Loening

Pete and Martha Eckerline

Edgepark Medical Supplies

Mrs. Franklin S. Edmonds

Pamela F. and Franklin S. Edmonds, Jr.

Edsal Manufacturing Co., Inc.

Education Management Corporation

Lia and Herm Edwards

Carl Edwards Motorsports

Debbie and Richard Egan/Debbie’s Dream

John and Ginger Eichhorn

James Ellis and Margaret Brady

Gary and Cindy Ellis

Dennis and Bonnie Ellman

Elvis Presley® Charitable Foundation

Emerald Cascade Restaurant

Emkay, Inc.

Mike and Sharon Ensign

Epic Systems Corporation

Pete and Wendy Ernaut

Ernst & Young

Annette S. Eskind and the Eskind Family Foundation

Es-O-En Dba Taco Bell

ESPN

David Ettinger M.D., D.M.D. and Jacqueline Ettinger

ExxonMobil

Marcia and Joel Faber

Mr. and Mrs. Brian and Robyn Fagen

Lindy and John Fain, OD

Families for a Cure

Bronwyn and Scott Farber

Farmington Bank

Federated Clover Investment Advisors

Federated Kaufman Fund Utsch, Hans

Kelly and Carl Fellbaum

Fenco

Bill and Kristin Fenech

Whitney and Peter Ferré

Fight for Children

Financial Concepts, Inc.

Karey and Michael Finch

Mr. Marvin Finkelstein

Caryn and Douglas Firebaugh Foundation

First Commonwealth

FiServ

Scott and Betsy Fishbone

Shelly and Scott Fisher

Tammy and Steve Fitzgerald

Ken and Jane Fitzsimmons

Joseph A. Fleck

Susan and Kevin Flynn

Focus Express Mail Pharmacy

Janet and Ken Follansbee

Fort Pitt Capital Group

Foster Parts

Daveen and Alan Fox

Melanie and Jeff Fox

FPD Brakes

Mr. John Robert Franke

Frankel Family Foundation

Sheri Frazier-Kesner

32


On

Or

su

pp

Or

T i

Jd

rF

RESEARCH RESOURCES

RES

ULT

S

Roughly half a million people in 230

cities nationwide participated in the

FY2010 Walk to Cure Diabetes.

33

“I try not to let diabetes affect what I want to do,” Mary says. “I’m not inhibited by it.”

In fact, the Lucases have created ways to remain proactive, productive, and positive in the face of the disease’s challenges. Parents Sarah and Don Lucas are the founders of Spring Fling – an annual fundraising event for JDRF’s Greater Bay Area Chapter that includes a golf tournament, a ladies luncheon and boutique, and a themed evening bash. Sarah now sits on the chapter’s Board, serving as Vice President of Special Events. Don, a venture capitalist who served on JDRF’s Silicon Valley Branch Board for six years, is a founding investor and Board member of Dexcom, one of the companies that provides continuous glucose monitors for research being funded by JDRF’s Artificial Pancreas Project.

Their involvement with type 1 diabetes began in November 1998, when the family was on the brink of another “next big thing.” With three children in tow, the Lucases were staying with friends for a couple of days while moving into a new home. When Mary, then seven, became very

ill, they rushed her to the hospital, where she was diagnosed with type 1, a disease the family knew little about at the time.

The Lucases were determined to keep life as normal and active as possible. As soon as they were settled into their new home, Sarah – already an avid charitable event planner – rented out a bowling alley, set out a donation box, and invited their friends to come out and play to support type 1 diabetes research. While researching organizations to send the proceeds to, she discovered JDRF.

The next year, when their bowling event brought in $40,000 for JDRF, the Lucases got a call from the Greater Bay Area Chapter’s executive director, who called their grassroots efforts impressive and asked if they would be interested in creating an annual chapter event. Sarah and Don agreed, and came up with the idea for Spring Fling. It began with inviting friends and colleagues to participate, and has grown into a multi-event community tradition that has raised nearly $5 million for JDRF. The 10th-anniversary Spring Fling is set for April 1, 2011, and the honorary committee – which celebrates those who have helped make it so successful year

after year – has a fundraising goal of $1 million.

Throughout its years of growth, Spring Fling has remained family-and-friends-oriented, much like the Lucases themselves, which makes them proud. Each year, the entire Lucas family is involved in planning and running Spring Fling, including Mary and her siblings, Jack (16), Kate (12), and Henry (10). Explains Sarah, “It’s marked on the family calendar each year much like a holiday…it’s part of the fabric of our lives. From now until there’s a cure, I see our family continuing this event.”

Sarah hopes her family’s story underscores the message that everyone can make a difference. “The point is to do something,” Sarah urges. “That’s what we try to model for our kids. That’s our message. But also have fun while you’re doing it.”

And it’s just this mantra, “do something,” that keeps the family positive and productive. It’s why Mary’s type 1 diabetes is an important detail in her life, but not its definition. Her life is hers to design, with all of her “next big things.”

At 18, an ambitious and enthusiastic Mary Lucas is on the brink of her “next big thing”: planning her move from Atherton, CA to New York City to study fashion design at Parsons, her dream since she was in grade school and making dresses out of fabric remnants. Being on the brink of the “next big thing” is a common theme for the entire Lucas family, and their vigorous approach to life is reflected in how Mary has managed her type 1 diabetes.

TurningChallenge

into possibilityLuCAs familyJd

rF i d

On

Or

su

pp

Or

T

34


Fred Meyer Stores

The Robert Freeman Ford Foundation

Fried, Frank, Harris, Shriver & Jacobson, LLP

Robert and Lori Frieling

Fringe Benefit Life Insurance

Frito-Lay

Fry Communications, Inc.

Michael and Elizabeth Gallagher

Lori and Greg Gallant

John and Lori Galley

Robert R. Galvin

Janie and Michael Gantt

Emma and Mark Garrett

Steven J. Gartner

Mr. and Mrs. Oscar Garza

Kim Gatlin

GBS Corporation

GE Asset Management

GE Capital

GE Foundation

Mary and James L. Geisman

Gene & Jerry Jones Family Charities

James and Janice George

Drs. David and Katie Gesensway

Gibbons P.C.

Gibson, Dunn & Crutcher, LLP

Gidick Family Trust

Gilbane Building Company

Cliff Gilbert-Lurie

Mike and Susan Gillfillan

James Gleason

Mark and Sue Gleason

Mark and Hanna Gleiberman

Globallogic, Inc.

Gohmann Asphalt/Construction, Inc.

Janie and Brian Gold

Goldman, Sachs & Co.

Charles and Rhonnie Goldstein

Jennifer and Alan Goldstein/Team Alaina

Daniel and Margo Good

Good Family Foundation

Janet Goodman

Ms. Diana Goodrich

The Goodyear Tire and Rubber Company

Andrew and Amy Gordon

Brenda and Robert Gordon

Mr. and Mrs. Keith and Wendy Gordon

Michael and Loren Gordon

Gabriela and Peter Gottlieb, M.D.

Joseph Grady

Steve Graham

Greater Houston Community Foundation

Edith Dee Green Foundation

Greenacre Properties

Jonathan and Stefanie Greenberg

Greenberg Glusker Fields Claman & Machtinger, LLP

Estate of Dorothy Greenfield

Debra and Bruce Grewcock

GRI Engineering & Development

Grillsmith Restaurants

Mr. Paul and Dr. Donna Roy Grogan

Estate of Abraham Gross

Group Health

Andy and Julie Gruber

Mrs. Bridget M. Guerin

Guess? Foundation

Christian and Cathy Haase

Hagans, Bob & Burdine

William Hake

Mrs. Sally Halff

Halliburton

Harry and Lynne Hallowell

Mr. and Mrs. Walter Halverstein

Clay Hammerstein

Hanify & King, P.C.

Carl and Val Hansen

The Mark and Anne Hansen Foundation

Harbert Management Corporation

Eric and Deidre Harger

Julia and Jeremy Harman

Jim and Janet Harris

Jennifer and John Hart

Mr. Kevin Harvey

Stan Hastings

Haugo Bancshares, Inc.

Joy and Ralph Hauser

Desmond and Jen Havilcek

Jeff and Christina Hawkins

Mr. Victor Haydel

Hilda Laura V. Haynes Family Foundation – Melissa M. Amice Haynes

Healthways

Dan and Carolyn Heard

The Helen G. Hauben Foundation

Julie and Michael Hellmers

Patricia and Gary Henn

Bruce Herring

Hershey Entertainment & Resorts

Hess Foundation, Inc.

Hewitt Associates

Heymann & Fletcher Esqs.

Jewel and Mark Hickman

Hickory Printing Solutions, Inc.

David and Dawn Hickton

Mr. and Mrs. John Hipp

HITT Contracting, Inc.

Hoag Memorial Hospital Presbyterian

Michael and Jennifer Hobbs

Mason Hoffman and Family

Mr. and Mrs. Thomas Hoffman, Jr.

Holiday Management Foundation, Inc.

Brad and Deb Hollinger

Emily and Steve Hollis

The Holzman Family Foundation

Home Box Office, Inc.

Chiu Has Hong

Russell Hoppenstein

Horne Brothers Construction, Inc.

Lorraine and Graeme Houston

Mrs. Helen M. Howard

Mr. and Mrs. Billy Howard

Howrey, LLP

HAS Commercial Real Estate

Janna Hubble

Jeff and Catherine Huge

Clayton and Gina Hughes

Greg Hughes

Joe and Marilyn Hughey

Roy A. Hunt Foundation

John Iberle

IBM Employee Services

ICT Group, Inc.

Estate of Mary E. Ide

Illinois Tool Works, Inc.

Frank Ingrassia and Elizabeth McCaul

Inserra Supermarkets

Interactive Concept Management, LTD.

Interdynamics, Inc.

International Bank of Commerce

Interpublic Group

Intuit

Ion Media Networks

International Paper Foundation

dO

nO

r s

up

pO

rT

i

Jdr

F

In FY2010 Team JDRF was

launched to support people in holding their own

fundraisers for JDRF.

RESEARCH RESOURCES

RES

ULT

S

Chris and Tonia Irion

Iroquis Avenue Foundation

Cindy and Jim Irvine

ITT Night Vision

Allen Ivester

J & J Family Foundation

The J.E. and Mildred Waggoner Family Foundation

J. Lawrence Khakis of Carmel

JP Morgan

Jabil Circuit

Darren and Terry Jackson

Katie and Steve Jackson

Jackson Family Wines

Arlene Jacobs, M.D. and Allen Feltman

Brandon and Kim Jacobs

Hal and Debby Jacobs

Irwin and Joan Jacobs

Jeff and Deni Jacobs

Paul and Stacy Jacobs

The James Family Foundation

Sean and Jennifer Jeffries

Cathy and Peter Jensen

Dr. and Mrs. E. Forrest Jessee, Jr.

Jig-A-Loo

Joe and Ora Vella

GE Johnson Construction Company

Greg and Tracy Johnson

The James Hervey Johnson Charitable Trust

Jay Johnson and Hannah Tenneson

Mrs. Jennifer U. Johnson

Jim and Laura Johnson

Ron and Karen Johnson

Rupert and Maryellie Johnson

Jones Lang LaSalle

Estate of John W. Jordan

John and Andrea Jordan

Josco

Catherine and Thomas Joyce

Sarah and Ron Jury

Chara Schreyer & Kadima Foundation

Bob and Marissa Kagle

Robert J. Kahn Foundation

Craig and Rose Kaintz

Jackie and Norm Kallan

Kansas City Chiefs Ambassadors Charitable Foundation

Kansas City Power & Light District

35

From heartbroken to heroic: A story of generous high-Achievers Mackin Family

When Larry and Suzanne Mackin’s daughter, Ali, began rapidly losing weight and feeling weak at age 14, they took her to the doctor, hoping that the problem could be easily fixed with a little nutritional guidance. But to their horrific surprise, tests showed Ali’s blood sugar was at 500, and she was rushed to the hospital. Type 1 diabetes had entered the Mackins’ world, and they knew life would never be the same.

Since that day, Larry and Suzanne have thrown themselves wholeheartedly into volunteering with and supporting JDRF to work for better treatments and a cure for Ali and everyone with type 1 diabetes. And even though Ali is now an adult – a recently married 26-year-old who works in the family business and is setting up her new home – Larry and Suzanne remain devoted to JDRF. As Suzanne says, “I don’t like to do anything halfway; I feel like I have to stick with things and carry them through fully.”

The Mackins’ contributions to their Oregon/Southwest Washington Chapter have been – and still are – extensive. Larry has served as a Board member for more than six years and was Board president for two. Larry and Suzanne have also been Gala co-chairs for five years and are major contributors to and catalysts of the event’s success. In fact, they are ongoing Gala sponsors and have donated auction items, given to Fund A Cure, and even provided transportation for auction items and other chapter donations. For a five-year stint, they were the Gala’s “Presenting Sponsors,” helping to ensure its success with a generous contribution of $20,000 a year. The family also holds JDRF fundraising events, including poker and golf tournaments. The Mackins have even enlisted their company – Mackin’s Auto Body – to become a Walk sponsor, form a Walk team, and sell Sneakers in its six locations. In recognition of all that they do, Larry and Suzanne were honored at the chapter’s 2002 Gala. Says Larry, “Every day, we try to make a difference with diabetes; it’s our passion.”

Carol and Edward Kaplan

Leon and Mary Ellen Kaplan

Kevin and Janet Katari

Katherine Herman Charitable Remainder Trust

Ira J. Kaufman Family Foundation

Jack Kay

KBR

Tonya and Michael Keith

Joan and Herb Kelleher Charitable Foundation

The Kelleher Corporation

Keller Family Foundation

Mr. and Mrs. Richard Kellner

Kemps

Kenan Advantage Group

Ken Kendrick

Margaret L. Kenyon Trust

Terri and Michael Kerber

Carla and Michael Kilbane

Mr. and Mrs. David Kim

Kingston Technology

The Kinney Family

Estate of Julia J. Klapec

Stephen Klar and Janice Gross

Kristin and Jim Klint

Mr. and Mrs. Todd Klumok

Knights of Pythias Diabetes Research Association

Mrs. Stephanie Knippel

Dr. John Knoedler

Knollwood Adopt a Charity Association

Katchen and Mark Knorringa

Tracy and Mike Koeppen

Mark Kogan

Jdr

F i dO

nO

r s

up

pO

rT

36

dO

nO

r s

up

pO

rT

i

Jdr

FMaJOr dOnOrs & parTners continued

when Jared Allen was a rookie for the National Football League’s Kansas City Chiefs in 2004, his roommate

received a Walk to Cure Diabetes fundraising letter from a friend’s son. Jared read it and was moved by the child’s description of the challenges of type 1 diabetes. It inspired him to pick up the phone.

“I was looking for something to get involved with,” he says. He talked first with the child’s father about living with diabetes and then with JDRF’s Yvonne Miller about how he might be able to help. He agreed to appear at a Walk awards dinner for the Kansas City Chapter – a first step that has evolved into a marathon relationship.

Today, Jared describes his many contributions to JDRF in a typically understated way: “I got involved with some kids, and it’s gradually grown over the years.” Yet that doesn’t begin to adequately describe what he’s done, especially for the Kansas City Chapter: appearing at the Dream Gala, initiating a “Sack Diabetes” fundraising program, serving as the Walk

Celebrity Chair, and representing JDRF at a variety of community fundraising events. On the national level, Jared appeared at Children’s Congress in 2009, offering support and inspiration to children with type 1 from across the nation.

Miller credits Jared’s involvement with boosting JDRF fundraising by more than $300,000, and she says his partnership has given the chapter an entrée into the entire Chiefs organization.

“Our relationship with Jared has evolved into so much more than him serving as our Celebrity Chair...he has gone from interested advocate to evangelist,” Miller says. “He truly has become part of the Kansas City Chapter family. He has visited kids in the hospital, gone to their baseball games, basketball games, high school football games, swim meets, and school plays.”

One of the most striking things about Jared’s involvement with JDRF is the fact that he has no direct experience with type 1 diabetes. “I knew the kids were great,” he says of his decision to become involved. “Just hanging around with the kids grew my relationships with the families, and I learned more and more about diabetes.”

In 2008, Jared joined the Minnesota Vikings, his talents rewarded with what at the time was the most lucrative contract ever for a defensive player. Since then, he has also become supportive of JDRF’s MinnDakotas Chapter, appearing in public service announcements, among other initiatives. Jared has also started his own charity, building homes for wounded war veterans. Still, he remains dedicated to JDRF.

One of the things that inspires him is JDRF’s results-oriented research. He has learned a lot about the search for a cure and understands the challenges involved. “It’s one of those things where on the research side, every step is one step closer, but I know these kids would like to see the complete cure altogether.” he says.

What keeps him committed are the kids and families he’s met.

“Big corporate events, sponsorships, and fundraising are all part of what you’ve got to do,” he says, “but it’s always good to hang out with the kids and families, see their struggles firsthand, and get to know them…I don’t even think of it as charity; I’m just hanging out with friends now.”

For Jared, the visibility he can bring to type 1 diabetes is secondary to what he brings to these families. “I think the

biggest thing…is the time I’ve spent with families,” he says. “Even if it’s just an hour to take the kids’ minds off the disease that they’re battling every day, that’s the greatest gift I can give them.”

JAReD ALLeN

One of the most striking things about Jared’s involvement with JDRF is the fact that he has no direct experience with type 1 diabetes.

Just Because he Cares: Jared Allen’s Inspiring Commitment

37

Seth Kogan

Florence and Chester Kolczewski

Darla and Jerry Kollar

KPMG

Kraco Enterprises, LLC

Harvey and Minna Kramer

Steven and Cindy Kramer

Carolyn and Morris Kremen

Ure and Dianne Kretowicz

Estate of Ruth M. Kroon

Mr. Michael Krupka and Dr. Anne Kubik

Mr. and Mrs. Frank Kudla

Laffey McHugh Foundation

Mr. Marshall Laitsch and Ms. Carolyn Powell

Lamar Bruni Vergara Trust

Estate of Gilbert E. Lamothe

Land O’Frost

Jim and Maggie Lang

Lannan Foundation

Las Patronas

The Lawton Family Fund

Mary and Jack Leary

Joann Leatherby and Dr. Greg Bates

Mr. and Mrs. Franc Lee

Leerink Swann & Co.

Matthew and Violet Lehrer

David Lewis

Geoffrey and Karen Lewis

Rick and Lisa Lewis

Lewis-Sebring Family Foundation

Elizabeth Liebman

Liner, Yankelevitz, Sunshine & Regenstreif, LLP

Joe and Debbie Lippincott/Lippincott & Lippincott

Robert and Elizabeth Lisowski

Little Feet and More, Inc.

Local Edge

Jacinta and Robert Loewen

Long Island Diabetes Support Foundation, Inc.

Lormar Foundation

James Lott

Estate of Barbara Louis

Louis Yager Cantwell Private Foundation

Louisiana CNI, LLC

Louisiana Machinery

Lowdon Family Foundation

Mr. and Mrs. Steve Lowit

Jacqueline and Richard Loynd

Lozier Foundation

Cheryl and Tom Lozowski

Forrest and Charlotte Lucas

The Lucas Family

Lucas Oil Products

Larry L. Luing Family Foundation

Kimberly Lund

Kristina and Marvin Lustiger

Richard Lutz

M & H Building Specialties, Inc.

M.D. Anderson Foundation

Mr. and Mrs. James MacDonald

Will MacKenzie

Mackin’s Auto Body

Macquarie Group Foundation

MacroGenics, Inc.

Heather and Jim Madden

Joe and Wendy Madden

Madison Square Garden

Jerome and Frances Magner

William Mahoney

Major League Baseball

Robin and Charles Malk

Mr. and Mrs. Hampton Mallis

Mr. and Mrs. Bob E. Mallory, Jr.

Peter and Catherine Malone

Mr. and Mrs. John M. Maloney, Jr.

Amir & Rosita Manocherian Family Foundation

Marathon Oil

Mr. and Mrs. Barry Margolis

Robert Margolis

Marina Medical Billing Services

Marion W. Minton, Walter J. Minton Foundation, Inc.

Mark Lauria Associates, Inc.

Markey’s Audio Visual

John and Lisa Marquardt

Jane and Z. Marshall

Melinda and John Marshall

Kara and John Martin

Massapequa Youth Lacrosse Club

Mattel, Inc.

Barbara and Hank Mawicke

W. David and Mary Maxwell

Louis Mayberg

Mark and Anna Maynard

McAlester Radio

Mr. and Mrs. Josh McCarter

Elizabeth and Jake McCarthy

Mr. and Mrs. Ken McClure

McConnell Development

Billie and Scott McCormick

McCownGordon Construction, LLC

Mr. and Mrs. Kyle McCoy

McCutcheon Enterprises, Inc.

Mr. and Mrs. Patrick J. McFeeley, Sr.

Mr. and Mrs. Patrick McFeeley, Jr.

Sharon McGill

Eric and Donna McGovern

Andy and Dan McGuire

Virginia McGuire Foundation

Marc and Mandy McIntyre

McKamish, Inc.

Kevin McKenna

McKesson – Greenville, TX

McNeil Nutritionals

MED3000, Inc.

Medical Center of Plano

Meguiar’s, Inc.

David W. Meier, Jr.

Meijer, Inc.

Menasha Corporation

Vickie and Bob Mercer

Mercy Medical Center

Nancy and Les Meredith

Merisant US, Inc.

Merrick Ventures, LLC

Estate of Robert H. Merrill

Merrill Companies, LLC

Merrill Lynch

Metro East Annual JDRF Golf Tournament Association

Foy and Judy Meyer

Michelin

Micrmetl

Mid-Hudson Valley Federal Credit Union

Elise Mikus

Milano Foundation

Cindy and Rich Miller

Diana and Mike Miller

Lisa and David Miniat

Pauline and Ronald Miniat

May Mitchell Royal Foundation

Howard and Judy Mock

Moe’s Southwest Grill

Molton Brown

Peter and Sarah Monaco

Montgomery Coscia Greilich/ExponentHR

Jdr

F i dO

nO

r s

up

pO

rT

JDRF Ride to Cure Diabetes

participants raised an average of

$4,100 each for diabetes research

in FY2010.

RES

EAR


Monument Realty

Moore and Van Allen

Morgan Keegan & Company, Inc.

Morgan Stanley-Investment Banking (NYC)

Thomas Morhaus

Alan Morris and Pia Exber-Morris

Mr. and Mrs. Robert Morrison

Julie and John Morrow

Michael and Jenna Morton

Mountainstar Healthcare

Patty Mozart

MSC Industrial Direct

Douglas Mueller

Sue and William A. Munck

Munck Carter, LLP

Mr. Anthony Murphy

Mr. and Mrs. Anthony Murphy

Payson and Grant Murray

Mutual of Omaha

Diana and Michael Myers

NASCAR

Nas-Walker

National Bank of Arizona

National Basketball Association

National Championship Hunt Foundation

National Philanthropic Trust

National Postal Mail Handlers Union

Mrs. Beatrice Naumann

Nauticon Imaging Systems

Molly and Skip Naylor

Laurence and Susan Nayman

The Nancy Lurie Marks Family Foundation

Nancy Near

NeBAA

Nebraska Heart Institute

Neil and Jane Golub Foundation

Neiman Marcus

Mr. Randall Nelson

Kathi and Dirk Nelson

Meeghan and Michael Nemeroff

Nestle Waters North America

Netezza Corporation

Dave and Esparanza Neu

New York Giants

New York Media, LLC

The New York Times Company

Newbury Comics

Newmont Mining Corporation

The News Corporation Foundation

Estate of Hilda Newton

Next Chapter Associates

NIC Holding Corporation

John and Lori Niehoff

Nipro Diagnostics

Sharon and Jack Nix

Noble Corporation

Peter And Stephanie Nolan

John and Linda Nordin

Cathy Nordling

Julie and Gary Nordlund

Phyllis Nordlund

Norkus Enterprises

Daniel and Janice Norman

Normandy Real Estate Partners

Robert and Jane Norris

Jean Norris and Vincent Norton

Dellora A. and Lester J. Norris Foundation

Northern Tool and Equipment

Northern Trust

Novartis Pharmaceuticals, Inc.

Novo Nordisk Pharmaceuticals

Lance and Lou Noyes

Oakland Athletics

Estate of Hubert O’Daniels

Susan and Stacy Oelsen

Old South Home Co.

Ollila Law Group

O’Melveny & Myers

Edmond and Alice Opler Foundation

Orange Coast Magazine

Winifred & William O’Reilly Foundation

Estate of Brenda Orr

Osborn & Barr

OSMC

Osram Sylvania

Jonathan and Donna Ostrau

Bank of America In Memory of Gunnar S. Overstrom

Bill and Norma Overton

Mary Ellen and Lee Owen

Owens Illinois

PACCAR

Pacers Sports & Entertainment

Donna Pacicca and Dominic Decicco

Penny and Ruffner Page

Steve and Tamara Pann

Mark and Kathy Papermaster

Chris and Shannon Parker

Mr. and Mrs. Howard Parker

Parker Hannifin Corporation

Paul Parsons/Team Jake

Elyse and George Pasha

Varsha and Vikas Patel

The Patricia & Clarke Bailey Foundation, Inc.

Kathy and Nathan Patterson

Mr. and Mrs. John Patterson

Dr. and Mrs. Net Payne

Karin and Philip Pead

Earl Peeples, M.D.

Bob and Leslie Penkhus

Bob Penkhus Volvo Mazda VW

Drs. Jennifer and William Pennoyer

Pepper Hamilton, LLP

PepsiCo Foundation

Eric Perakslis

Perfection Hy-Test

John Peterson

Alan and Bonnie Petsche

The Pfeiffer Family Foundation

Pfizer, Inc.

The PGA TOUR / THE PLAYERS

PHH Mortgage

Philadelphia CBOA

Physicians Plus Insurance Corporation

Lynn Pieper

Vicki and Robert Pierce

Anne and Robert Pillion

Nancy and Bret Pilney

Pinnacle Bancorp, Inc.

PlainsCapital Bank

Jill Plant and James Nichols

Platte Valley Bank of Missouri

Dena and Michael Plumer

The Plymouth Rock Foundation

PNC Private Wealth Management

PNC Foundation

Dr. and Mrs. Kevin Pogreba

Patrick and Laura Pohlen

Matthew and Judith Pollack

Polo Ralph Lauren

Mr. Christopher Pongratz

Porsche Club of America Chicago Region, Inc.

Gerry Powderly and Adriana Bauza

Thomas and Tina Powderly

38

dO

nO

r s

up

pO

rT

i

Jdr


www.facebook.com/myjdrf

RESEARCH RESOURCES

RES

ULT

SMore than 50,000 people follow JDRF on

Facebook.

39

David and Virginia Powell

John Powell

Prairie Meadows

Pratt & Whitney

Praxair

Linda and Richard Price

Mr. and Mrs. Lev. H. Prichard, IV

Print Shop Open

Proliance International, Inc.

Promontory Financial Group, LLC

Pro’s Ranch Market

Mr. and Mrs. Michael Provenzano

Providence Medical Group

Prudential Financial

Mr. and Mrs. John Pruitt

Pulse EFT Association

Quaero, a CSG Solution

Charles and Jeri Eckhart Queenan

Quest Diagnostics

Quicksilver Resources

Jay and Kathy Rains

Mr. and Mrs. Richard Randall

Craig Rauchle and Julie Weintraub

Raymond James Financial, Inc.

Raynbow Foundation

RB Distribution

Red Ball Oxygen

Red Rock Distributing Company

Mr. and Mrs. Ralph Reed

Kevin, Christine and Shea Reilly

Lisa and Chris Reilly

Mr. and Mrs. Ben Reitzes

The Related Companies

Remsa of America

Renée West

Don and Margie Reynolds

Reynolds American

Reznick Group

Mr. and Mrs. John Rice

Mr. and Mrs. Chris and Ginny Rich

Charles L. Richards

Richards Manufacturing/ETI

Camilla and Scott Richardson

Jim and Karin Riley

Richard and Nancy Riley

Jim Ritchie Family Foundation

Mrs. Tammy J. Ritchie

William Rittwage

RiverStone Resources, LLC

Robert J. Kahn Foundation

Anthony and Rosemary Roberto

Mitch and Jill Roberts

Peter and Leslie Robinson

Mr. and Mrs. Bud Roche

The Rockland Country Club Foundation, Inc.

Ms. Ellen Rollins

Mr. and Mrs. Gary Rollins

Ms. Nancy Rollins

Romenesko Family Dentistry

Mr. and Mrs. David Roos

Tom Roose and Joanne Thompson

Rosemary Haggar Vaughan Family Foundation

Rosler Family Foundation

Ross & Yerger Insurance, Inc.

The Arthur J. Roth Family Foundation

Marty Rumble

Mr. and Mrs. Frederick Leroy Russell, Jr.

Mrs. Doris Russell

Steve and Claudia Russell

Kerry and Timothy Ruth

RX Stat

Ryan Companies

S&D Coffee, Inc.

S.S. Medici Cosma & Damiano

Dave and Janice Sachs

Safeco Insurance

Saint Louis Children’s Hospital

Saks Fifth Avenue

Mr. and Mrs. Allen Salikof

Salt River Project

Terry Saltzberg

Sam Roosth Foundation

Samson

Samuels & Associates

San Diego Parrot Head Club, Inc.

Cary and Valerie Sandler

The Sandra Atlas Bass & Edythe & Sol G. Atlas Fund, Inc.

Sangamo BioSciences, Inc.

Estate of Mildred Sansbury

Michael and Diane Sapir

Neil and Sheryl Sarnak

Scafco Corporation

The Paul Scammell Foundation

Mr. William and Vicki Schaefer

Mr. and Mrs. Joel Schaller

Schlesinger Companies

Mark and Maria Schlossberg

Schlumberger

Ed and Donna Schmidt

Shawna and Eric Schoonveld

Mark and Jackie Shrekgast

Chris and Krista Schultz

Dr. Peter Schultz

Schulze and Burch Biscuit Co.

Peter and Kathleen Schwalje

Terri and Marc Schwartz

Mr. and Mrs. Thomas Schwartz

Scottrade

Seinfeld Family Foundation

Sellers, Richardson, Holman, West

Seneca Niagra Casino & Hotel

Thomas and Lyn Shea

Bill and Julie Sheley

Shell Oil Products United States

Mary Sheridan

John and Mary Sherman

The Sherwin-Williams Company

Jack and Sue Shilling

Shoes For Crews

John Shrewsberry and Ereca Miller

Portia Whitaker Shumaker Fund at the San Diego Foundation

Sigma-Aldrich

Mr. and Mrs. Jeff Silk

Lin and Mike Simmonds

Simmons Browder Gianeris Angelides & Barnerd, LLC

The Sidney, Milton and Leoma Simon Foundation

Mari Sinton-Martinex

Skanska USA Building, Inc.

Mike and Beth Skorich

Estate of Natalie Slesinger

Mike and Lisa Smart

Smart Pill Corp.

Ed Smith

Ellen and Lew Smith

Patty and Greg Smith

Mr. Steve Smith

Smith Family – In Memory of Jennifer Catherine Smith

Smith International

Velocity Solutions

Jeffrey and Mindy Sosland

Neil and Blanche Sosland

Southwest Securities

The Spano Family Charitable Foundation

Sperling Brothers Foundation

Jdr

F i dO

nO

r s

up

pO

rT

RES

EAR


Some 24 million Americans have

either type 1 or type 2 diabetes.

40

Mr. and Mrs. Joshua Speyer

Tishman Speyer

The Spiritus Gladius Foundation

Anne and Bernard Spitzer

Alana Spiwak and Sam Stolbun

Sprint

St. Louis SportsServices, LLC

STMicroelectronics, Inc.

The Julia Carell Stadler Foundation

Mr. and Mrs. Tom Standish

Robert and Connie Stanley

Staples

Stefani’s Children’s Fund

Steve and Betty Sterett

Bruce and Judith Stern

Thomas D. and Denise R. Stern Family Foundation

Mr. Mark Stevens

George and Sue Stewart

Teresa and Glen Stewart

Mr. David Stierle

John and Denise Stilley

Sting Alarm, Inc.

Stony Apparel

Storandt Pann Margolis

Stradley Ronan Stevens & Young, LLP

Strauss Foundation of Trust

Luke and Scotti Strockis

Jim and Susan Stuart, Jr.

Lee R. Stuart Family Foundation

Studley, Inc.

Heather and Tom Sturgess

Sub-Zero Foundation

Suffolk Construction Company

Dan and Katie Sullivan

Rich and Gaby Sulpizio

Summit Credit Union

Sun Capital Partners Foundation, Inc.

Sunrise Hospital and Medical Center

SuperValu

The Supreme Master Ching Hai International Association

Terese and Jeffery Surges

Susie’s Deals

Madalene and Wayne Swetnam

Scott and Tina Swisher

SXC Health Solutions, Inc.

Sysco Corporation

The Taddeo Family

Bill and Karen Talbert

Susan Talbot

Anonymous in honor of Mark Tamoshunas

Tanamera Construction

Target Corp.

Tarson Investment, LLC

The Taubman Company

Taylor International Corporation

TD Ameritrade

TD Bank

Team Zachary

Tech Group North America, Inc.

Gina Tega and Ali Partovi

James and Laurie Theiss

Telesis

John and Ethel Templeton Fund

Joni Elaine Templeton Charitable Trust

Terry World

Terumo Medical

Texas Children’s Hospital

Texas Health Resources

Mr. and Mrs. Alex Theriot

Karen and James T. Thielens

Walt Thirion

Jennifer Thoele

Mr. Ryan Thomas

Thomas E. Jernigan Foundation

Kay and Don Thorp

Jelindo and Sandee M. Tiberti

Time Warner, Inc.

Cynthia B. Tomlinson Foundation

Jan and John Totushek

Tricia and Randy Touchstone

Mr. Andy Townend

Mr. John F. Trexler

Tri City National Bank

TriMark SS Kemp

Troutman Sanders

Scott and Vonnie Trumble

Trying2help.com

Cindy and Bob Tucci and Jeff Wolfe

Rob and Gina Tuckey

Tucson Medical Center

Chris and Tracy Turner

Wayne and Susan Turner

ULLICO, Inc.

United Biosource Corporation

United Parcel Service

United States Steel Corporation

United Way of Metropolitan Chicago

Universal Lighting Technologies

Universal Weather and Aviation

University of New Mexico Hospitals

University of Pittsburgh

University of Texas Southwestern Medical Center

US Bank

U.S. Trust, Bank of America Private Wealth Management

USS-Posco Industries

Utah Del, Inc.

Valentine Capital Asset Management

Philip L. Van Every Foundation

Amy Roth and Jack Van Valkenburg

Mr. Eric Van Zwisler (Australia)

Vanderbilt University Medical Center

Vanguard Charitable Endowment Program

Variety Children’s Charity of New England

Sherrie and Anthony Varrichio

Sarah and Porter Vergon

Cliff and Jill Viner Family Foundation

ViraCor-IBT Laboratories, Inc.

Visa

Vista-Pro Automotive

Visteon Climate Control

VML Foundation

Mr. Roger F. Vorce

Vornado/Charles E. Smith

Anne Lyons and C.J. Voss

Dawn and John Vresics

W P W Foundation

W.T. Young, LLC

Judy and David Wachs

Mr. Laurence Wald

Mr. and Mrs. Richard and Edith Wald

Estates of Seymour and Gloria Wald

Milton and Miriam Waldbaum Family Foundation

The Waldman Family

Chris and Terri Walker

Estate of Lillian K. Walker

Martha and Dave Waller

Walmart

J. and J. Walsh Family Charitable Fund

Walsh and Nicholson

dO

nO

r s

up

pO

rT

i

Jdr


Diabetes and its complications cost more than $174 billion a

year in the U.S.

RESEARCH RESOURCES

RES

ULT

S

hope spans generations of FamilyMonier Family

41

The Warburg Pincus Foundation

Jeanne and James Ward

The Warranty Group/TWG Holdings, Inc.

Denise and Peter Waters

Marjorie Waters

Mr. and Mrs. Robert E. Watts

Mr. and Mrs. Robert H. Watts

Missy and Chuck Wayland

Kevin and Erin Wehrenberg

James and Ellen Weil

Dr. and Mrs. E. Hunter Welles, III

Julie and Dennis Wellner

Wellpoint

Tobias and Kristin Welo

Bob and Kay Welsh

The Robert & Kathleen Welsh Foundation

The Welter Foundation

Alton and Millie Wendzel

Robin and Bradley Werner

Alice and Bruce Werstak

Bob and Gloria Werth

Wescon Construction

West Corporation

Westchester Capital Management

Western Athletic Clubs, Inc.

Jeff Westphal

Pam and Jim Whalen

Harvey and Sheryl White

Michael and Sharon White

Harvey and Annette Whittemore

Brett and Louise Wickard

Mr. Randy Wild

Wild Flavors, Inc.

Willa’s Workshop

Mr. and Mrs. A. Kelly Williams

Sarah and Daniel Williams

Williams & Connolly

Kim Williams-Paisley

Willow House

Mr. and Mrs. James Winchester

Patricia and Steven Winegar

Ann and Marc Winthrop

Greg and Barbara Wipf

Bud and Barb Wise

The Ken Wishall Family

Mr. and Mrs. Barry Wolf

Richard and Jane Wolf

Gregg Wolfe/Kaplan, Leaman, and Wolfe Court Reporters

Claire Wolfe

Lawrence and Stacey Wolin

Wolverine World Wide, Inc.

Patricia and Larry Wright

Terry and Dana Wright

Xcoal Energy and Resources

XL Group

XTO Energy

Mr. and Mrs. Michael Yackira

Mr. and Mrs. James L. Yeargan

Yocum Oil Company

Yoh Group

Beverly and Bruce Young

Mary Jeanette Yuengling Charitable Remainder Trust

The Zaltzman Family

Janice and Jason Zeid

Todd and Julianne Zeile

Lauri and Bruce Zessar

Frank and Andrea Ziegler

Zurich Financial Services

In 2007, after having lived with type 1 diabetes for more than 34 years and having lost a grandmother to its complications, Melinda Monier didn’t think she could be any more ready to see an end to the disease. Then she got a heartbreaking phone call: her 28-month-old grandson Rory had also been diagnosed with type 1 diabetes.

As soon as Rory’s parents started a family JDRF Walk team called Rory’s Mission in 2008, Melinda seized the opportunity to kick her JDRF involvement into high gear. She immediately arranged for a Bag of Hope for Rory and became active in her local Louisiana Chapter, participating in the 2008 and 2009 Walks and taking part in an inspirational video for the Gala. Currently, Melinda serves as a committee-at-large member of her chapter’s Board. Melinda is endlessly motivated by seeing how Rory’s parents throw themselves into the cause wholeheartedly, supporting JDRF through a number of fundraising events. Melinda says that “the hope and the faith that a cure will be found in Rory’s lifetime” also helps to guide her extensive commitment.

Recently, Melinda and her husband, Jerry, took their JDRF commitment to the next level by including the foundation in their estate plans. “The reason JDRF is mentioned in our wills is because we feel that they are the best hope for a cure,” she explains. Melinda stresses that “a cure for type 1 diabetes is critical,” especially since she worries that her “two small granddaughters could also be at risk.” Melinda is most heartbroken by seeing children suffer with the disease. “Children should be able to be children,” she says. “They should not have to be concerned with blood sugar highs and lows, carb counting, insulin injections, finger sticks, and all the complications associated with type 1 diabetes.”

Today, Rory is a happy five year old who loves playing sports and is an inspiration to his grandmother. “He loves snow cones,” she says. “He calls me Mim, and one day after a game he said, ‘Mim, you and me, we’re gonna get the sugar-free cones because we have type 1 diabetes.’” As Melinda puts it, “My grandson inspires me everyday. I have become a better diabetic because I have to set an example for him.”

Jdr

F i dO

nO

r s

up

pO

rT

42

Anonymous (46)

Beth Adams

Thomas Anderson

Ann Ansel

Kelly and Mark Anthony

Andrea and Mark Bacik

Angela and Michael Barber

Deborah J. Barrett

Teresa Bath

Ann and Thomas Behan

Jayne Beyer

Skene and Rebecca Black

Robin Bosch

Carol Bradway

Katherine and Rob Burgener

Virginia and Lawrence Capek

Kristen and David Carter

William Cederholm

Lee Clark

Rita Cohen

Cindy Lorenston Cook

Erica and Greg Cowan

Sean Curran

Illa and Kevin Davis

Linda and Bill Dettelback

Jennifer and John Dilling

Lawrence Dolce

Kathi and Bruce Donnor

Dennis and Jo Ann Dworshak

Mary Eckhert

Robert Edelbrock

Allyson and Ruedy Edgington

Jay Ellett

KC England

Jenny and Neill Erdossy

Priscilla Call Essert

Megan and John Farley

Rick Ferguson

Olivia and Grady Foster

Lisa Sailor-Fowler and Bob Fowler

Mary and Terry Franke

Greg Gallant

Chaprell Gazzerro

Lani Gendron

Camden Gooch

Melissa and Michael Gray

Stephen Grieco

James Griffin

Jim Griffith

Gabriella Guazzo

Lori and Jody Hanks

Frances Hansen

Errol Harris

Lisa and Mark Haslam

Eileen and Mike Hendren

Jack Hickethier

John Hipp

Tea Hoffman

Mary Hollock

Donald S. Huddleston

George B. Hutchinson

Rosalind and David Ingber

Dave Johnson

Gloria Jones

Deborah and Steven Jones

Stephanie Jones

Kristen Judd

Laurie and Tom Kane

William Keller

Shirley and Gary Kerkow

Caroline Kinsey

Rachelle and Randal Kline

Lisa and Todd Klumok

Bonnie Kunzel

Teresa and Kevin Lentz

Leigh MacHaffie

Tina Maden

Dr. Ira and Susannah Marks

Patrick McKowen

James McLaughlin

Janice and David Merdgen

Mrs. Charles Monasee

Melinda and Jerry Monier

Deborah Newsome

Jon Nordenberg

Steve Peterson

Dr. Kevin and Becky Pogreba

Earl and Juli Postol

Melissa and Thomas Reedy

Michelle and Frank Reynaud

Shawn Reynolds

Irene and John Ronzia

Kenneth Roosth

The BETA Society recognizes individuals who have included JDRF as a beneficiary in their estate plans. The listing below features BETA Society members who made new planned giving commitments to JDRF in FY2010.

BeTA sOCIeTY MeMBeRs

dO

nO

r s

up

pO

rT

i

Jdr

F

Over the past six years, JDRF has distributed over

50,000 Bags of Hope to children newly

diagnosed with type 1 diabetes.

RESEARCH RESOURCES

RES

ULT

S

43

Jon Rosa

Carol and Walt Rosebrough

Linda and Kreg Rowe

Jennifer and Joel Russell

Dr. and Mrs. Joseph Sansevere

Joshua Sauberman

Paul Schlesinger

Erica and Scott Schuetze

Susan and Dr. Lenny Segal

Dr. and Mrs. Sam Shatkin

Jenny and Tom Sheahan

Marc Sheffler

Ruth and Kevin Shelly

John Shrewsberry and Ereca Miller

Kevin Smith

Elizabeth Squires

Mark Stevens

Judy and Bob Strohl

Judy Summers

Todd R. Teter

Karen and Ted Thielens

Dana Thomas

Suzanne and Todd Turnlund

Holly and Robert Udell

Lynda Ufer

Bob and Meg Van Schoorl

Laura Vartanian

Tania Violette

Allan Wearing

Julie Weiss

Linda and Hank Wells

Marcus Wesche

Charles Wexler and Stephanie Wexler Malone

Mark Whitehead

Shea Wills

Thomas Wood

Janet and Robert Yaroma

A great-great-uncle’s LoveElmer Livingston

Elmer Livingston was a kind but private man. He lived into his 90s, staying active in body and mind until his later years. Before retirement, Elmer made a living buying royalties in the oil business; he saved his earnings and invested them carefully. Though Elmer was a dedicated and meticulous manager of his stocks and wealth, it was his family that was the true center of his world. His nephew Jack explains, “Elmer didn’t show a lot of emotion, but he had a lot of emotion.”

Nowhere is Elmer’s love for his family more evident than in the trust he created, in which he left over $114,000 to JDRF. The impetus behind his generous gift was his two great-grand-nieces, Clara Livingston and Meghan Fisher, each of whom lives extremely successfully with type 1 diabetes. Clara, now 14 – a wonderfully accomplished student, violinist, softball player, and swimmer – was diagnosed at age four. She attended Children’s Congress and since 2002 has participated in her Illinois Chapter’s Walk, for which her family’s team has raised over $100,000. Clara’s mother, Gretchen, who served on the Illinois Chapter’s Board, says, “She’s an amazing kid who’s done an amazing job of managing her diabetes.”

Meghan, 16, is also an outstanding student and athlete: She has won the Oklahoma State Gymnastics competition for her age group three times, twice after her diagnosis at age 14. Meghan’s parents, Bob and Wendi, have become highly involved with their local Tulsa Green Country Chapter, particularly in the Gala. Wendi says that since her diagnosis, “Meghan says she sees herself stronger.”

Elmer would be enormously proud to see his two great-grand-nieces thriving so beautifully today, and to know that his generous contribution is going directly toward improving the lives of Clara, Meghan, and everyone living with type 1 diabetes.

Jdr

F i dO

nO

r s

up

pO

rT

The Juvenile Diabetes Research Foundation International wishes to express its deepest gratitude to the following members of the JDRF family for their generous donations of $10,000 or more to the JDRF Stem Cell Research Fund. These donors, and many others, have provided JDRF with more than $19 million since the Fund’s inception in FY2002. Their vision and leadership ensure that JDRF can continue to vigorously pursue stem cell research, which holds such promise for a cure for type 1 diabetes and its complications.

Co-Chairs: Mary Tyler Moore & s. Robert Levine, M.D.

Anonymous (4)

The Judith and Jean Pape Adams Charitable Foundation

Alagem Capital Group

Susan Alberti AO Hon LLD*

Mrs. Kathleen Albrecht and Mr. Pete McCormick

Andrew Family Charitable Foundation

Helene and Allen Apter

Ares Management LLP

Veronica Atkins

Karen Barfoot*

The Bloom and Mittel Founding Families of the Greater Bay Area Chapter

Quent and Inez Boyken

William K. and Delores Brehm

Broidy Capital

Capital Guardian Trust

Richard and Elizabeth Carrell

Chartwell Charitable Foundation

Dean and Shirley Chenoweth

Clarity Partners

Irene and Seymour Cohen

Comerica Bank

Ken and Sherry Corday

Thomas and Wendy Cramer

Creative Arts Agency

Alison and Richard Crowell

Jaime Davila

Lawrence J. and Florence A. DeGeorge Charitable Trust

Danny DeVito and Rhea Perlman

Eunice L. Dwan 1991 Irrevocable Trust

EMWIGA Foundation

Entertainment Industry Foundation

Joel and Marcia Faber

Allen Feltman and Arlene Jacobs, M.D.

Mr. and Mrs. Simon C. Fireman

First Republic Bank

Marilyn & Dr. Gerald Fishbone

Greg Fisher and Family

The Ella Fitzgerald Charitable Foundation

Jeanine Forman-Ham

The Lauren Gatlin Stem Cell and Beta Cell Research Initiatives Fund

Geffen Foundation

James Gorton

44

sTeM CeLL ReseARCh FuND

dO

nO

r s

up

pO

rT

i

Jdr

F

www.trials.jdrf.org

More than 15,000 people

have registered with JDRF’s Clinical Trials Connection to gain information on

type 1 clinical trials.

RESEARCH RESOURCES

RES

ULT

S

45

Greenberg, Glusker, Fields, Claman and Machtinger

Clay Hammerstein and Family

Michael Heine*

Michael and Loretta Helfant

Stephen and Roey Higgs*

Hille Foundation

Irell and Manella, LLP

Frank and Sophia Jackson*

Robert Wood Johnson IV

Julie and John Johnston

Damien and Yvonne Jordan

Marjorie & Maxwell Jospey, In Memory of Their Daughter, Jane Jospey Cobb

Marjorie & Maxwell Jospey Foundation

WM Keck Foundation

The Kennedy/Marshall Company

Brent Kessel and Britta Bushnell

Taras and Kristen Kihiczak

Laurie and Alec Kouyoumdjian

Gilda and Murray Lappe

Latham & Watkins, LLP

Eason and Ellen Leake

The Lee Family Fund

Lewis-Sebring Family Foundation

Richard and Jacqueline Loynd

The Joseph D. Maio Scholarship Fund

Sharon and Tom Malloy

Alfred Mann

Fred and Susan Mardell

Andy and Terry Marx Foundation

Douglas Matheson-Illinois Tool Works

Helen and William Mazer Foundation

Brian McCarthy

Michael and Kimberly McClain

Charles and Aniela McCool

In Honor of Allison McDonough

McDonough Family Foundation

The Giles W. and Elise G. Mead Foundation

Marianne and G. Allen Mebane

Shelly and Ira Meister

Medtronic MiniMed

Steven G. Mihaylo

Mr. and Mrs. Gary Millican, In Honor of Alexander Millican and In Memory of Roy E. Millican, Jr.

Mary Tyler Moore and S. Robert Levine, M.D.

Jim and Susan Nelson

Nicholl Family Foundation, Inc.

O’Melvany and Meyers

Bert C. O’Neal, In Honor of Lisa and Jack Reed and Elizabeth Shannon

In honor of Kathy & Mark Papermaster, Kathy & Steve Papermaster and Gail Papermaster & Dave Mattson

Lorna and Gary Pederson

Paramount Pictures

Lea and Barry Porter

PR 21

Kay and Jay Proops

Mitchell and Nina Quaranta

Steve and Anne Rader

Mr. and Mrs. Jack Reed, Jr.

Remy Investors

Jamie and Anthony Ressler

In Honor of Mr. and Mrs. David I. Roos, Jr. and Family, In Memory of Debbie Roos Hoppenfeld

Jan M. Roswig

Sheila Royles*

Renee and Robert T. Samuels

Scudder Investments and Deutsche Asset Management

In Honor of Elizabeth O’Neal Shannon

Elizabeth O’Neal Shannon and Jack Herbert Shannon

In Honor of Mrs. JoAnn Shull and In Memory of Her Daughter, Candy

Mrs. JoAnn Shull

Mr. James M. Shure and Family

Kelly and David Siegel

Reagan Silber-Edge TV

Sandra and Alan Silvestri

Victoria Mann Simms

Skadden Arps

Marianne and Roy C. Smith

Sony Pictures Entertainment

Brenda and James Souers

In Honor of Barry and Mimi Sternlicht

Jim and Susan Stuart, Jr.

Tiscornia Foundation

TransAmerica

Trench Shoring Co.

Jami and Nicolaus Von Heidegger

Warner Brothers Pictures

Casey Wasserman

Charles and Mary Jane Wick

Cynthia Wick and Channing Gibson

Doug Wick and Lucy Fisher

David and Terry Wohlberg

Mr. and Mrs. William T. Young, Jr.

Anne and Allen Zaring

Julianne and Todd Zeile

Robert Zemeckis – Image Movers

Donor to the Nucleus Fund

Jdr

F i dO

nO

r s

up

pO

rT

Names in gold indicate donors making gifts during FY2010Names in boldface indicate a donor to the Nucleus Fund *Australia

Nearly every JDRF chapter in the

U.S. provides trained mentors to assist people with type 1

diabetes.

RES

EAR


46

JDRF is pleased to recognize the following donors for their generous investments in specific JDRF-funded research studies. By helping to fund JDRF’s research priority areas, these donors play a critical role in aiding our efforts to improve the lives of – and ultimately find a cure for – people with type 1 diabetes. The following are named grants that received funding during FY2010.

NAMeD gRANTs

dO

nO

r s

up

pO

rT

i

Jdr

F

Estate of Helene Alley in Memory of Theodore Whitlock and Theodore Whitlock, Jr.

Pancreatic Stem Cells

Derek Van der Kooy, Ph.D.

University of Toronto, Toronto, CAN

In Honor of Jonathan P. Altman Research Grant Award

TXNIP, A Novel Therapeutic Target for Type 1 Diabetes

Anath Shalev, M.D.

University of Wisconsin – Madison, Madison, WI, USA

Diane Gay, Mike & Tamra Gay In Honor of Parker Gay & in Memory of His Grandfather, Francis V. Gay

nPod Coordinating Center

Mark Atkinson, Ph.D.

University of Florida, Gainesville, FL, USA

Estate of Bernard Jaffee

Involvement of Heparanase in Diabetic Nephropathy

Israel Vlodavsky, Ph.D.

Technion – Israel Institute of Technology, Haifa, ISR

In Honor of Ahmed Mahfooz Latif

Regulation of CD4 T cell Islet Entry

Dario Vignali, Ph.D.

St. Jude Children’s Research Hospital, Memphis, TN, USA

Lewis–Sebring Family Foundation

In support of Dr. Alexander Chervonsky

University of Chicago, Chicago, IL, USA

Vickie & Robert Mercer

Novel Pathways to Expansion of Functional Beta Cell Mass

Christopher B. Newgard, Ph.D.

Duke University Medical Center, Durham, NC, USA

The Proctor & Gamble Company Career Development Award

Regulatory T cells, Immune Privilege and Islet Allograft Tolerance

Zhenhua Dai, M.D., Ph.D.

University of Texas Health Center, Tyler, TX, USA

Rancho Santa Fe Women’s Fund

Drug Development for Beta Cell Regeneration

Fred Levine, M.D.

University of California San Diego, San Diego, CA, USA

In Memory of Lisl Schuhmann

Accomplishing Type 1 Diabetes Immune Regulation in the Pancreas

Manuela Battaglia, Ph.D.

Fondazione Centro San Raffaele del Monte Tabor, Milano, ITA

In Honor of Tops Markets, LLC

A Future Without Diabetes Career Development Award

Molecular Profile of the Human Diabetic Kidney Disease

Katalin Susztak, M.D., Ph.D.

Albert Einstein College of Medicine, Yeshiva University, Bronx, NY, USA

The Louis Vance Family In Honor of Kathryn Vance Research Grant

Targeted Expression of Insulin to Intestinal Encocrine Cells

Timothy Kieffer, Ph.D.

University of British Columbia, Vancouver, BC, CAN

The Wattles Family Foundation in Honor of Conner Wattles

Cell Fate Potential of Putative Progenitor Cells from Telomerase Tg Mice

David Breault, M.D., Ph.D.

Children’s Hospital, Boston, MA, USA

The Sybil and David Yurman Postdoctoral Fellowship Award

Identifying Urinary Biomarkers of Diabetic Nephropathy

Maryam Afkarian, M.D., Ph.D.

Massachusetts General Hospital (The General Hospital Corp.), Boston, MA, USA

www.jdrf.org/satrequest

JDRF’s School Advisory Toolkit has been downloaded by over 10,000 people since its launch in

February 2008.

RESEARCH RESOURCES

RES

ULT

S

47

Jdr

F i Fina

nC

iaL r

ep

Or

T

fInancIal rePorT

48

62%

60%

7%

22%

20%

6%

11%

12%

Fin

an

Cia

L r

ep

Or

T i

Jd

rF

82%

FUNCTIONAL EXPENSES $191.0Mfor the year 2010

n Management & General $13.0M

n Fundraising $21.4M

Research & Education Programs $156.6M

n Public Education $38.7M

n Research Support $117.9M

PUBLIC SUPPORT AND REVENUE $207.1Mfor the year 2010

n Contributions $45.3M

n International Affiliate Transfers $24.7M

n Revenue $13.5M

n Special Events, Including Walk (net) $123.6M

Independent Auditors’ Report

The Board of DirectorsThe Juvenile Diabetes Research Foundation International:

We have audited the accompanying statements of financial position of The Juvenile Diabetes Research Foundation International (the

Foundation) as of June 30, 2010 and 2009, and the related statements of activities, functional expenses, and cash flows for the years

then ended. These financial statements are the responsibility of the Foundation’s management. Our responsibility is to express an

opinion on these financial statements based on our audits.

We conducted our audits in accordance with auditing standards generally accepted in the United States of America. Those standards

require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material

misstatement. An audit includes consideration of internal control over financial reporting as a basis for designing audit procedures

that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Foundation’s

internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis,

evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant

estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide

a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of The Juvenile

Diabetes Research Foundation International as of June 30, 2010 and 2009, and the changes in its net assets and its cash flows for the

years then ended in conformity with U.S. generally accepted accounting principles.

New York, New YorkOctober 4, 2010

sTATeMeNTs OF FINANCIAL pOsITION

The Juvenile Diabetes Research Foundation International June 30, 2010 and 2009

49

See accompanying notes to financial statements.

Jdr

F i Fina

nC

iaL r

ep

Or

T

LIABILITIES AND NET ASSETS

Liabilities

Accounts payable and accrued expenses $ 12,610 7,323

Liabilities related to split-interest agreements 2,554 2,598

Deferred special events revenue 4,524 4,346

Research grants payable (note 9) 152,664 180,152

Total liabilities 172,352 194,419

Commitments and contingencies (note 10)

Net assets (accumulated deficit):

Unrestricted 466 (20,868)

Temporarily restricted (note 11) 25,675 31,122

Permanently restricted (note 11) 5,414 5,208

Total net assets 31,555 15,462

Total liabilities and net assets $ 203,907 209,881

(in thousands) 2010 2009

ASSETS

Cash and cash equivalents $ 23,118 42,311

Investments (note 3) 146,062 134,535

Accrued income 5,081 3,770

Contributions receivable, net (note 6) 23,094 23,467

Prepaid expenses and other assets 2,792 3,568

Fixed assets, net (note 7) 3,760 2,230

Total assets $ 203,907 209,881


sTATeMeNTs OF ACTIVITIes

50

The Juvenile Diabetes Research Foundation International Years ended June 30, 2010 and 2009

Fin

an

Cia

L r

ep

Or

T i

Jd

rF

ExPENSES (NOTE 5):

Program services:

Research support, net (note 9) 117,920 — — 117,920 109,912 — — 109,912

Public education 38,657 — — 38,657 36,072 — — 36,072

156,577 — — 156,577 145,984 — — 145,984

Supporting services:

Management and general 13,001 — — 13,001 11,930 — — 11,930

Fund-raising 21,417 — — 21,417 19,665 — — 19,665

34,418 — — 34,418 31,595 — — 31,595

Total expenses 190,995 — — 190,995 177,579 — — 177,579

Change in net assets 21,334 (5,447) 206 16,093 (29,983) (4,102) 51 (34,034)

Net assets (accumulated deficit) at beginning of year (20,868) 31,122 5,208 15,462 9,115 35,224 5,157 49,496

Net assets (accumulated deficit) at end of year $ 466 25,675 5,414 31,555 (20,868) 31,122 5,208 15,462


UnrestrictedTemporarily

RestrictedPermanently

Restricted Total UnrestrictedTemporarily

RestrictedPermanently

Restricted Total

PUBLIC SUPPORT AND REVENUE:

Public support and revenue:

Contributions $ 31,517 13,763 — 45,280 32,509 8,136 — 40,645

Special events:

Proceeds 149,003 — — 149,003 147,140 — — 147,140

Direct donor benefits (25,430) — — (25,430) (27,095) — — (27,095)

Contributions from affiliates (note 8) 24,693 — — 24,693 18,567 — — 18,567

Total public support 179,783 13,763 — 193,546 171,121 8,136 — 179,257

Revenue (loss):

Investment return (loss) (note 3) 13,104 8 206 13,318 (36,390) 5 51 (36,334)

Other 224 — — 224 622 — — 622

Total revenue (loss) 13,328 8 206 13,542 (35,768) 5 51 (35,712)

Net assets released from restrictions 19,218 (19,218) — — 12,243 (12,243) — —

Total public support and revenue $ 212,329 (5,447) 206 207,088 147,596 (4,102) 51 143,545


sTATeMeNTs OF FuNCTIONAL expeNses

51


Jdr

F i Fina

nC

iaL r

ep

Or

T

(in thousands) 2010

PROGRAM SERVICES SUPPORTING SERVICES

Research support

Public education Total

Management and general Fund-raising Total

Total expenses

Research grants, net (note 9) $ 107,547 — 107,547 — — — 107,547

Payroll and related expenses 6,701 25,591 32,292 8,656 14,069 22,725 55,017

Printing and promotional expenses 284 2,086 2,370 489 2,019 2,508 4,878

Office rent and related expenses, including depreciation and amortization 1,624 6,305 7,929 2,548 3,329 5,877 13,806

Meetings and conferences 786 2,045 2,831 380 782 1,162 3,993

Professional services 869 995 1,864 379 390 769 2,633

Miscellaneous 109 1,635 1,744 549 828 1,377 3,121

Total functional expenses 117,920 38,657 156,577 13,001 21,417 34,418 190,995

Percentage of total functional expenses 61.74% 20.24% 81.98% 6.81% 11.21% 18.02%

Costs of direct benefits to donors 25,430

Total expenses and costs of direct benefits to donors $ 216,425

2009

PROGRAM SERVICES SUPPORTING SERVICES

Research support

Public education Total

Management and general Fund-raising Total

Total expenses

Research grants, net (note 9) $ 100,870 — 100,870 — — — 100,870

Payroll and related expenses 6,045 22,965 29,010 7,798 12,543 20,341 49,351

Printing and promotional expenses 242 2,560 2,802 523 1,936 2,459 5,261

Office rent and related expenses, including depreciation and amortization 1,190 5,776 6,966 2,173 2,822 4,995 11,961

Meetings and conferences 722 1,665 2,387 451 1,122 1,573 3,960

Professional services 776 1,648 2,424 509 634 1,143 3,567

Miscellaneous 67 1,458 1,525 476 608 1,084 2,609

Total functional expenses 109,912 36,072 145,984 11,930 19,665 31,595 177,579

Percentage of total functional expenses 61.90% 20.31% 82.21% 6.72% 11.07% 17.79%

Costs of direct benefits to donors 27,095

Total expenses and costs of direct benefits to donors $ 204,674


CASH FLOWS FROM OPERATING ACTIVITIES:

Change in net assets $ 16,093 (34,034)

Adjustments to reconcile change in net assets to net cash used in operating activities:

Net (appreciation) depreciation in fair value of investments (11,002) 40,027

Depreciation and amortization 1,989 960

Changes in operating assets and liabilities:

Accrued income (1,311) 1,608

Contributions receivable 373 3,109

Prepaid expenses and other assets 776 (574)

Accounts payable and accrued expenses 5,287 (4,643)

Split-interest agreements (44) (282)

Deferred special events revenue 178 (260)

Research grants payable (27,488) (21,003)

Net cash used in operating activities (15,149) (15,092)

CASH FLOWS FROM INVESTING ACTIVITIES:

Purchase of fixed assets (3,519) (1,381)

Purchase of investments (24,014) (14,863)

Proceeds from sale of investments 23,489 53,046

Net cash (used in) provided by investing activities (4,044) 36,802

Change in cash and cash equivalents (19,193) 21,710

Cash and cash equivalents at beginning of year 42,311 20,601

Cash and cash equivalents at end of year $ 23,118 42,311

sTATeMeNTs OF CAsh FLOWs

52



Fin

an

Cia

L r

ep

Or

T i

Jd

rF

NOTes TO FINANCIAL sTATeMeNTs

53

June 30, 2010 and 2009 (Amounts in thousands)

1. ORGANIzATIONThe mission of The Juvenile Diabetes Research Foundation International (the Foundation) is to find a cure for diabetes and its complications through the support of research.

The Foundation solicits contributions from the public and engages in various fund rais-ing activities. Funds raised are used to support Type 1 diabetes research. In addition, the Foundation engages in advocacy efforts aimed at increasing federal funding of Type 1 dia-betes research.

The financial statements of the Foundation include the accounts of the Foundation and its Chapters located throughout the United States. The Foundation has international affiliates located in Canada, Australia, the United Kingdom, and a number of other countries. The financial statements of those organizations are not included in the accompanying financial statements since the Foundation does not exercise control over the management and op-erations of the international affiliates.

The Foundation is a not for profit organization exempt from federal income taxes un-der Section 501(c)(3) of the Internal Revenue Code, organized under the laws of the Commonwealth of Pennsylvania.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIESA. BASIS OF PRESENTATIONThe Foundation’s financial statements are prepared on the accrual basis of accounting in accordance with standards established by the Financial Accounting Standards Board (FASB) for external financial reporting by not for profit organizations. Accordingly, net assets of the Foundation and changes therein are classified and reported as follows:

Unrestricted Net Assets—Net assets that are not subject to donor imposed restrictions.

Temporarily Restricted Net Assets—Net assets subject to donor imposed restric-tions that will be met either by actions of the Foundation or by the passage of time.

Permanently Restricted Net Assets—Net assets subject to donor imposed re-strictions, which stipulate that the principal be maintained permanently by the Foundation, but permit the Foundation to expend part or all of the income and gains derived there from.

Revenues and gains and losses on investments and other assets are reported as changes in unrestricted net assets unless limited by explicit donor imposed restrictions or by law. Expenses are reported as decreases in unrestricted net assets.

When a time restriction ends or a purpose restriction is accomplished, temporarily restricted net assets are reclassified to unrestricted net assets and reported in the statements of activities as net assets released from restrictions.

B. CONTRIBUTIONSContributions, including unconditional promises to give (pledges), are reported as rev-enues in the period received or pledged. Contributions with purpose or time restrictions that are not met in the same reporting period as received are reported as increases in temporarily restricted net assets and are reclassified to unrestricted net assets when the purpose or time restrictions are met. Contributions subject to donor imposed stipulations that the corpus be maintained permanently are recognized as increases in permanently restricted net assets.

Conditional promises to give are not recognized until they become unconditional, that is, when the conditions on which they depend are substantially met. Contributions of as-sets other than cash are recorded at their estimated fair value. Contributions expected to be received after one year are discounted at a risk adjusted rate of return. Amortization of the discount is recorded as additional contribution revenue in accordance with the donor imposed restrictions, if any, on the contribution.

Contributions received for future special events, primarily walk events, are recorded as deferred revenue and are recognized as revenue in the fiscal year the event takes place, which is generally within one year.

The Foundation administers two types of split interest agreements – Charitable Gift Annuities and Charitable Remainder Trusts. With Charitable Gift Annuities, the Foundation receives cash or marketable securities from a donor in exchange for an annuity to be distributed for a fixed amount over the lifetime or lifetimes of the donor or other benefi-ciaries. Upon the death of the annuitant or survivor of the annuitants, the Foundation is entitled to full use of the remainder. With Charitable Remainder Trusts administered by the Foundation, the Foundation receives donated assets as trustee under a trust agree-ment established by the donor in exchange for an income stream to be distributed to the donor and/or other beneficiaries over a specified period of time. The distribution to the donor or other beneficiaries may be a fixed dollar amount (an annuity trust) or percent-age of the fair value of the trust as determined annually (unitrust). Upon the termination of the trust, the Foundation is entitled to full use of the remainder. For both Charitable Gift Annuities and Charitable Remainder Trusts, a related liability is recorded for the ac-tuarially determined present value of the obligation to the annuitant or annuitants. The discount rates used to calculate the liability range between 2.6% and 8.2% at June 30, 2010. For Charitable Gift Annuities, the assets received are held as general assets of the Foundation, and the annuity liability is a general obligation of the Foundation.

C. CASH AND CASH EQUIVALENTSCash equivalents consist of money market accounts, demand notes, savings accounts, and certificates of deposit purchased with original maturities of three months or less, except for such instruments purchased by the Foundation’s investment managers as part of their investment strategies.

D. INVESTMENTSThe Foundation’s investments, including assets related to split interest agreements, are reported at fair value based upon quoted market prices or, with respect to hedge funds and convertible preferred stock, at estimated fair value. The estimated fair value of hedge funds, as a practical expedient, is the net asset value as provided by the investment managers, and evaluated for reasonableness by the Foundation. The fair value of the convertible preferred stock of a private company is estimated by the Foundation based upon audited financial statements and other information provided by the company. Due to the inherent uncertainties of these estimates, these values may differ from the values that would have been used had a ready market existed for such investments.

E. FIxED ASSETSFixed assets, which consist of furniture, equipment, and leasehold improvements, are recorded at cost. Depreciation is provided on a straight line basis over the estimated useful lives of the assets, which approximate three to ten years for furniture and equip-ment. Leasehold improvements are amortized on a straight line basis over the shorter of the life of the asset or the lease term.

F. FAIR VALUE OF FINANCIAL INSTRUMENTSFinancial instruments are defined to include: cash and cash equivalents, investments, receivables, assets related to split interest agreements, accounts payable, and liabilities related to split interest agreements. The fair value of investments is discussed in note 3. The carrying amount of the Foundation’s remaining financial instruments approximates fair value.

G. ALLOCATION OF JOINT COSTSThe Foundation allocates joint costs between fund raising and program services or management and general in accordance with Accounting Standards Codification (ASC) No. 958-720, Accounting for Costs of Activities of Not for Profit Organizations and State and Local Governmental Entities That Include Fund Raising.

H. USE OF ESTIMATESThe preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingencies at the date of the financial statements and the reported amounts of revenues and expenses during the year. Significant estimates made in the preparation of the financial statements include fair value of alternative investments, net realizable value of contributions receivable, and functional expense allocation. Actual results could differ from those estimates.

I. FUNCTIONAL ALLOCATION OF ExPENSESThe costs of providing the various programs and other activities have been summarized on a functional basis. Accordingly, certain costs have been allocated among the programs and supporting services areas that were benefited.

J. NEW ACCOUNTING STANDARDSIn 2010, the Foundation adopted the disclosure requirements of Accounting Standards Update (ASU) No. 2009 — 12, Fair Value Measurements and Disclosures – Investments in Certain Entities That Calculate Net Asset Value per Share (or its Equivalent), with respect to investments within its scope. The Foundation had adopted the measurement provisions of this guidance in 2009.

In 2010, the Foundation adopted ASU 2009 — 06, Implementation Guidance on Accounting for Uncertainty in Income Taxes and Disclosure Amendments for Nonpublic Entities, in conjunction with its adoption of FASB Interpretation No. 48, Accounting for Uncertainty in Income Taxes (now included in ASC Subtopic 740 10, Income Taxes – Overall). FASB Interpretation No. 48 addresses the accounting for uncertainties in income taxes recognized in an organization’s financial statements and prescribes a threshold of more-likely-than-not for recognition and derecognition of tax positions taken or expected to be taken in a tax return. There was no significant impact on the Foundation’s financial statements as a result of the adoption of this guidance.

3. INVESTMENTSInvestments at June 30, 2010 and 2009 consisted of the following:

2010 2009Cash and cash equivalents $ 16,000 —Equity mutual funds Domestic 18,626 16,962 Foreign 2,636 2,410Convertible preferred stock 4,934 4,934Fixed income mutual funds Corporate 9,714 28,383 Government 14,565 7,380Hedge funds 79,587 74,466 Total investments $ 146,062 134,535

Included in investments are amounts related to Charitable Gift Annuities and Charitable Remainder Trusts totaling $2,177 and $2,193, respectively, at June 30, 2010 and $1,928 and $2,040, respectively, at June 30, 2009.

Jdr

F i Fina

nC

iaL r

ep

Or

T

54

nOTes TO FinanCiaL sTaTeMenTs continued

The Foundation’s investments are exposed to various risks, such as market and credit risks. Because of the risk associated with such investments, it is possible that change in their values will occur and that such changes could materially affect the Foundation’s financial statements. The Foundation is exposed to credit risk in the event of nonper-formance by the issuers of the fixed income securities. However, the Foundation does not anticipate such nonperformance.

Assets and liabilities reported at fair value are required to be classified within a fair value hierarchy, which gives preference to the use of observable inputs over unobserv-able inputs. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The three levels of the fair value hierarchy are as follows:

• Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that a reporting entity has the ability to access at the measurement date.

• Level 2 inputs are other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly.

• Level 3 inputs are unobservable inputs for the asset or liability.

Most investments classified as Level 2 or 3 consist of shares or units in investment funds as opposed to direct interests in the funds’ underlying holdings, which may be marketable. Because the net asset value reported by each fund is used as a practical expedient to estimate the fair value of the Foundation’s interest therein, its classifica-tion in Level 2 or 3 is based on the Foundation’s ability to redeem its interest at or near the date of the statement of financial position. If the interest can be redeemed in the near term, the investment is classified in Level 2. The classification of investments in the fair value hierarchy is not necessarily an indication of the risks, liquidity, or de-gree of difficulty in estimating the fair value of each investment’s underlying assets and liabilities.

The following table presents the fair value hierarchy of investments as of June 30, 2010:

Total Level 1 Level 2 Level 3Cash and cash equivalents $ 16,000 16,000 — —Equity mutual funds Domestic 18,626 18,626 — — Foreign 2,636 2,636 — —Convertible preferred stock 4,934 — — 4,934Fixed income mutual funds Corporate 9,714 9,714 — — Government 14,565 14,565 — —Hedge funds 79,587 — 75,138 4,449 Total investments $ 146,062 61,541 75,138 9,383

The following table presents the fair value hierarchy of investments as of June 30, 2009:

Total Level 1 Level 2 Level 3Equity mutual funds $ Domestic 16,962 16,962 — — Foreign 2,410 2,410 — —Convertible preferred stock 4,934 — — 4,934Fixed income mutual funds Corporate 28,383 28,383 — — Government 7,380 7,229 151 —Hedge funds 74,466 — 61,598 12,868 Total investments $ 134,535 54,984 61,749 17,802

Information with respect to the strategies of those investment funds which are re-ported at estimated fair value based upon net asset value per share (or its equivalent) is as follows (amounts included are as of June 30, 2010):Long only global ex U.S. equity securities ($9,908) – includes investments in compa-nies that are believed to have overlooked value as well as event driven stocks selling at discounts to their intrinsic values. Investments are in long positions, predominately in developed markets outside of the United States.Long only emerging markets equity securities ($4,887) – includes investments in companies that are believed to have overlooked value as well as event driven stocks selling at discounts to their intrinsic values. Investments are in long positions, pre-dominately in emerging market countries.Multi-strategy hedge funds ($13,611) – includes investments in funds that pursue multiple investment strategies in an attempt to diversify risks and reduce volatil-ity. Capital allocated to each of the strategies, as well as geographical areas, varies depending on market opportunities.Equity long/short hedge funds ($18,561) – includes investments in funds that invest both long and short in equities. Investments are also made in fixed income securities and funds, depending on market conditions.Distressed debt hedge funds ($7,329) – includes investments in funds that attempt to invest opportunistically in troubled companies. Investments encompass distressed debt, private equity, real estate, high yield bonds, and a number of hedge fund strategies. Real assets ($13,943) – includes investments in liquid energy, real estate, and natural resources equities, as well as investments in commodities.Fixed income securities ($11,348) – includes investments in sovereign and invest-ment grade corporate bonds – both in the United States and globally. Investments also include the most senior debt of riskier, non-investment-grade companies.

The limitations and restrictions on the Foundation’s ability to redeem or sell these investments, as well as the convertible preferred stock, vary by investment. Based upon the terms and conditions in effect at June 30, 2010, the Foundation’s Level 2 and 3 investments can be redeemed or sold as follows: AmountsLess than a month $ 9,908Monthly 10,792Quarterly 54,438Annually 2,225Biannually 2,224More than 2 years 4,934 $ 84,521

The following table presents a reconciliation of Level 3 investments for the years ended June 30, 2010 and 2009: 2010 2009Balance at beginning of year $ 17,802 11,274 Transfer to Level 2 (9,554) — Net realized and unrealized gains 1,135 528 Purchases — 6,000Balance at end of year $ 9,383 17,802

The components of investment return and its classification in the statements of activi-ties for the years ended June 30, 2010 and 2009 were as follows: 2010 Temporarily Permanently Unrestricted restricted restricted TotalInterest and dividends $ 2,280 8 28 2,316Net appreciation 10,824 — 178 11,002 $ 13,104 8 206 13,318

2009 Temporarily Permanently Unrestricted restricted restricted TotalInterest and dividends $ 3,644 5 44 3,693Net (depreciation) appreciation (40,034) — 7 (40,027) $ (36,390) 5 51 (36,334)

Investment expenses relating to investment advisors, managers, and custodians and other bank charges are recorded as reductions to interest and dividend income. Investment expenses totaled $686 and $556 for the years ended June 30, 2010 and 2009, respectively.

4. RETIREMENT PLANThe Foundation has a defined contribution pension plan, which covers substantially all employees. The Foundation’s expense for the years ended June 30, 2010 and 2009 was $994 and $508, respectively.

5. ALLOCATION OF JOINT COSTSIn 2010 and 2009, the Foundation conducted activities, principally direct mail, that in-cluded fund raising appeals as well as program components. The joint costs incurred were allocated as follows:

2010 2009Public education $ 1,599 1,595Management and general 297 314Fund-raising 2,351 2,363 Total $ 4,207 4,272

6. CONTRIBUTIONS RECEIVABLEContributions receivable at June 30, 2010 and 2009 consisted of:

2010 2009Gross contributions receivable, due in: Less than one year $11,942 10,957 One to five years 12,990 14,579 Thereafter 163 372 25,095 25,908Less: Allowance for doubtful accounts (1,344) (1,324) Unamortized discount to present value, at rates ranging from 1.00% to 5.50% (657) (1,117) $ 23,094 23,467

Contributions receivable have been discounted to their present value at the rate at the time the original unconditional promise to give was made.

Fin

an

Cia

L r

ep

Or

T i

Jd

rF

55

7. FIxED ASSETS

Fixed assets at June 30, 2010 and 2009 consisted of:

2010 2009Furniture and equipment $ 5,568 6,010 Leasehold improvements 1,687 2,054 7,255 8,064Less accumulated depreciation and amortization (3,495) (5,834) Fixed assets, net $ 3,760 2,230

8. CONTRIBUTIONS FROM AFFILIATESDuring the years ended June 30, 2010 and 2009, the Foundation received contributions from affiliates as follows:

2010 2009JDRF - Canada $ 15,586 7,908JDRF - Australia 7,202 9,306JDRF - United Kingdom 1,599 1,183JDRF - Greece 37 65JDRF - Denmark 74 —JDRF - Israel 195 105 $24,693 18,567

JDRF Australia’s 2010 and 2009 contributions include $3,457 and $6,116, respectively, funded by the Australian Government as part of the JDRF Islet Transplantation Program (ITP) in Australia. The program, which began in 2007, funds JDRF approved grants at Australian medical and research institutions to address the basic science surrounding preclinical approaches to improve islet transplantation techniques.

JDRF Canada’s 2010 contributions include $7,883 related to a joint funding agreement with the Federal Economic Development Agency for Southern Ontario as part of the JDRF Canadian T1D Clinical Trial Network. The program funds JDRF- approved grants to conduct clinical trials to further the development and/or commercialization of an artificial pancreas for diabetics and to establish a Clinical Trial Network in Southern Ontario in order to facilitate and coordinate the conduct of Phase I and II Clinical Trials.

9. RESEARCH GRANTS PAYABLEResearch grants payable at June 30, 2010 and 2009 consisted of:

2010 2009Amounts expected to be paid in: Less than one year $ 150,420 168,837 One to five years 2,269 11,585 Subtotal 152,689 180,422Less discount to present value, at rates ranging from 1% to 1.71% (25) (270) Total $ 152,664 180,152

Research grant expense is net of any grant refunds, reductions, or terminations. These adjustments were $13,178 and $52,928 for the years ended June 30, 2010 and 2009, respectively.

10. COMMITMENTS AND CONTINGENCIES

A. RESEARCH GRANTSAs of June 30, 2010, there were conditional research grant commitments of $102,453, which will be recognized in the Foundation’s financial statements when the conditions have been substantially met, and are currently estimated to be payable as follows:

2011 $ 73,1852012 27,2122013 1,3082014 748 $102,453

B. LEASESEffective January 1, 1995, the Foundation entered into a 15 year lease agreement for executive office space in New York City. In 2001, the Foundation leased additional office space in the same building. Rent expense for the executive office was $1,605 and $1,369 for the years ended June 30, 2010 and 2009, respectively. The Foundation was also re-imbursed for certain construction costs associated with leasehold improvements. The leasehold improvements and a corresponding deferred credit were recorded in 1995, both of which were amortized on a straight line basis over the term of the lease, which expired on December 31, 2009. The Foundation did not renew this lease.

On August 3, 2009, the Foundation entered into a new lease agreement and relocat-ed its national headquarters during December 2009. The new lease commenced on September 1, 2009 for a 10 year term. Annual rent will be $1,269, increasing to $1,353 after the fifth year. Rent expense is recognized on a straight-line basis and, accordingly, a deferred rent credit has been recorded. At June 30, 2010, a credit of approximately $1,000 is included in accounts payable and accrued expenses.

The Foundation is also obligated under various leases for space occupied by certain Chapters. Rent expense including maintenance costs for the Chapters was $3,687 and $3,744 for the years ended June 30, 2010 and 2009, respectively.

Rental commitments for all leases are as follows:

2011 $ 5,2652012 4,6802013 3,5332014 2,4882015 2,0992016 1,827Thereafter 5,130 $ 25,022

C. LINE OF CREDITOn February 19, 2010, the Foundation entered into an agreement with JP Morgan Chase for an unsecured line of credit in the aggregate amount of $10 million. The term of the agreement expires January 29, 2011. The line of credit was unused as of June 30, 2010.

11. NET ASSETS

A. TEMPORARILY RESTRICTED NET ASSETSAt June 30, 2010 and 2009, temporarily restricted net assets were available for the fol-lowing purposes:

2010 2009Future periods, principally contributions receivable and split-interest agreements $ 24,319 29,733Diabetes Care Coalition program (know your A1C) — 1,014Various research projects 1,356 375 $ 25,675 31,122

B. PERMANENTLY RESTRICTED NET ASSETSAt June 30, 2010 and 2009, the investment return derived from permanently restricted net assets was expendable to support:

2010 2009General activities $ 1,576 1,576Research projects: Artificial Pancreas Project 2,000 2,000 Virginia Mason Research Center 1,838 1,632 $ 5,414 5,208

The Foundation’s endowment consists of four individual donor restricted endow-ment funds established for a variety of purposes. The Foundation has interpreted Pennsylvania law as requiring the preservation of the fair value of the original gift as of the gift date of the donor restricted endowment funds absent explicit donor stipu-lations to the contrary. As a result of this interpretation, the Foundation classifies as permanently restricted net assets (a) the original value of gifts to the permanent en-dowment and (b) accumulations of investment returns to the permanent endowment made in accordance with the direction of the applicable donor gift instrument, when applicable. The four endowment funds are invested in fixed income mutual funds. The Foundation has no board designated endowment funds.

The following tables present the changes in the Foundation’s donor restricted endow-ment funds for the years ended June 30, 2010 and 2009: 2010 Temporarily Permanently Unrestricted restricted restricted TotalEndowment net assets at June 30,2009 $ — — 5,208 5,208Investment income 397 — 28 425Net appreciation (realized and unrealized) 495 — 178 673Appropriation for expenditure (892) — — (892)Endowment net assets at June 30, 2010 $ — — 5,414 5,414

2009 Temporarily Permanently Unrestricted restricted restricted TotalEndowment net assets at June 30,2008 $ — — 5,157 5,157Investment income 626 — 44 670Net appreciation (realized and unrealized) 20 — 7 27Appropriation for expenditure (646) — — (646)Endowment net assets at June 30, 2009 $ — — 5,208 5,208

12. SUBSEQUENT EVENTSIn connection with the preparation of the financial statements, the Foundation evalu-ated subsequent events through October 4, 2010, which was the date the financial statements were available for issuance, and concluded that no additional disclosures are required.

Jdr

F i Fina

nC

iaL r

ep

Or

T

ChApTeRs & AFFILIATes

56

Ch

ap

Ter

s &

aFF

iLia

Tes

i

Jd

rF

JDRF has over 100 locations worldwide, including chapters and branches active throughout the United States and affiliates in eight countries. JDRF chapters and affiliates host Walks, Galas, and other fundraising events and programs to support the JDRF mission. They also offer support, guidance, and a sense of community for people with type 1 diabetes and their families. Please visit www.jdrf.org for information about JDRF activities near you.

AlabamaAlabama Chapter, Birmingham

ArizonaDesert Southwest Chapter, PhoenixSouthern Arizona Branch, Tucson

ArkansasGreater Arkansas Chapter, Little RockNorthwest Arkansas Branch,

Fayetteville

CaliforniaGreater Bay Area Chapter, San FranciscoInland Empire Chapter, RiversideLos Angeles Chapter, Los AngelesNorthern California Inland Chapter,

SacramentoOrange County Chapter, IrvineSan Diego Chapter, San Diego

ColoradoColorado Springs Branch,

Colorado SpringsRocky Mountain Chapter, Denver

ConnecticutFairfield County Chapter, NorwalkGreater New Haven Chapter, HamdenNorth-Central Connecticut/Western

Massachusetts Chapter, Farmington

DelawareDelaware Branch, Wilmington

District of ColumbiaCapitol Chapter, Washington, DC

FloridaCentral Florida Chapter,

Altamonte SpringsFlorida Suncoast Chapter, SarasotaGreater Palm Beach County Chapter,

West Palm BeachNorth Florida Chapter, JacksonvilleSouth Florida Chapter, Ft. LauderdaleTampa Bay Chapter, St. Petersburg

GeorgiaGeorgia Chapter, Atlanta

HawaiiHawaii Chapter, Honolulu

IllinoisIllinois Chapter, Chicago

IndianaIndiana State Chapter, IndianapolisNorthern Indiana Branch, South Bend

IowaEastern Iowa Chapter, Cedar RapidsGreater Iowa Chapter, Johnston

KentuckyKentuckiana Chapter, Louisville

LouisianaLouisiana Chapter, Baton RougeNew Orleans Branch, New Orleans

MarylandMaryland Chapter, Linthicum

MassachusettsNew England/Bay State Chapter,

Wellesley

MichiganMetro-Detroit/Southeast Michigan

Chapter, SouthfieldMichigan Great Lakes West Chapter,

Grand Rapids

MinnesotaMinnDakotas Chapter, Bloomington

MississippiMississippi Chapter, Jackson

MissouriKansas City Chapter, Kansas CityMetro-St. Louis/Greater Missouri

Chapter, St. Louis

NebraskaLincoln Chapter, LincolnOmaha Council Bluffs Chapter,

Omaha

NevadaNevada Chapter, Las VegasNorthern Nevada Branch, Reno

New HampshireNorthern New England Branch,

Manchester

New JerseyCentral Jersey Chapter, ShrewsburyMid-Jersey Chapter, East BrunswickNorthern New Jersey/Rockland County

Chapter, Englewood CliffsSouth Jersey Chapter, Cherry Hill

New MexicoNew Mexico Branch, Albuquerque

New YorkCentral New York Chapter, LiverpoolGreater Adirondack Region Branch,

Glens FallsHudson Valley Branch, Wappingers FallsLong Island Chapter, MelvilleNew York City Chapter, New York CityBrooklyn/Queens Branch, New York CityStaten Island Branch, New York CityNortheastern New York/Capital Region

Chapter, East GreenbushRochester Chapter, RochesterWestchester County Chapter,

White PlainsWestern New York Chapter, Amherst

North CarolinaCharlotte Chapter, CharlottePiedmont Triad Chapter, GreensboroTriangle/Eastern North Carolina

Chapter, Raleigh

OhioGreater Cincinnati Chapter, CincinnatiGreater Dayton Chapter, DaytonMid-Ohio Chapter, ColumbusNortheast Ohio Chapter, IndependenceAkron/Canton Branch, IndependenceNorthwest Ohio Branch, Toledo

OklahomaCentral Oklahoma Chapter,

Oklahoma CityTulsa Green Country Chapter, Tulsa

OregonOregon/Southwest Washington

Chapter, Portland

PennsylvaniaCentral Pennsylvania Chapter, LemoyneEastern Pennsylvania/Delaware

Chapter, Bala CynwydEast-Central Pennsylvania Branch,

Bala CynwydNorthwestern Pennsylvania Branch,

ErieWestern Pennsylvania Chapter,

Pittsburgh

Rhode IslandRhode Island Branch, Warwick

South CarolinaPalmetto Chapter, ColumbiaWestern Carolinas Chapter, Greenville

TennesseeEast Tennessee Branch, KnoxvilleMiddle Tennessee Chapter, BrentwoodWest Tennessee Branch, Collierville

TexasAustin Chapter, AustinGreater Dallas Chapter, DallasGreater Ft. Worth/Arlington Chapter,

Ft. WorthHouston Gulf Coast Chapter, HoustonPanhandle Branch, AmarilloSouth-Central Texas Chapter,

San Antonio

UtahUtah Chapter, Salt Lake City

VirginiaCentral Virginia Chapter, RichmondGreater Blue Ridge Chapter, RoanokeTidewater Chapter, Virginia Beach

WashingtonInland Northwest Branch, SpokaneJDRF Northwest Chapter, SeattleSeattle Guild, SeattleSouth Sound Branch, Seattle

West VirginiaWest Virginia Branch, Charleston

WisconsinNortheast Wisconsin Chapter, MenashaSoutheastern Wisconsin Chapter,

WauwatosaWestern Wisconsin Chapter, Madison

JDrf affiliates

JDRF AustraliaSt. Leonards, NSW

JDRF CanadaMarkham, Ontario

JDRF DenmarkCopenhagen

JDRF GermanyHeidelberg

JDRF IndiaSalt Lake, Kolkata

JDRF IsraelTel Aviv

JDRF MexicoMexico City

JDRF United KingdomLondon

59

fY2010 board of DirectorsDiane Adams

Fernando Aguirre

Dick Allen

Shannon Allen

Richard K. Bonness

John Brady

Mary Elizabeth Bunzel

Mitchell H. Caplan

Dayton Coles

Cynthia Ford

Chip Halverson

Michael Hendren

Robert R. Hindle

Steve Hitchins

Judy M. Hunt

Francis J. Ingrassia

Robert Wood Johnson IV

Richard Kirkland

Ellen Leake

Richard Levy

John Madden

James F. McDonald

Patrick McFeeley

Leo F. Mullin

David W. Nelms

George Nethercutt

Nettleton S. Payne, M.D.

David Rehr

Lewis R. Runnion

Glen E. Tullman

Michael L. White

William T. Young, Jr.

Anne Zaring

Ex officio: James C. Tyree

fY2010 board of chancellorsSusan Alberti AO Hon LLD

Don Aron

Robert Auerbach

Aubrey W. Baillie

Gordon D. Barker, R.Ph.

Maureen Barunas

Joan Beaubaire

Crandall Bowles

Erskine Bowles

Max C. Chapman, Jr.

Sanford Cloud, Jr.

Judi Cochran

Ross A. Cooley

Don Corrao

Lee Ducat

Samuel D. Ewing, Jr.

Gerald Fishbone, M.D.

Joseph Gardner, Ph.D.

Eileen Gelick

Robert D. German, Esq.

David Glusman

Krayna Golfman

Marilyn Gomm

William Graves

Roslyn Greenspon

Eric Harkna

Margaret Conn Himelfarb, M.P.H.

Michael J. Hopkins, Esq.

Terry A. Jackson

Fran Jacoby

Ardy Johnson

Dave Johnson

Larry King

Robert N. Klein II

Anne Lacey

Joann Leatherby, Esq.

Jan Leeper

Stephen Leeper, D.D.S.

S. Robert Levine, M.D.

Carol Lurie

James M. Lurie, Esq.

John J. McDonough

Steven M. Merdinger

Mollie Miller

Penny Moseley

Leah Mullin

J. Richard Munro

Katharine S. Overlock

Willard J. Overlock, Jr.

Penn Payne, Esq.

Margery D. Perry

Gail Pressberg

Sandra Puczynski, Ph.D.

Charles J. Queenan III

Kenneth M. Rich

Mark Rubenstein

Steven T. Ruby, M.D.

Pam Sagan

Bob Samuels

Alyce Satsky

Helaine Shiff

Sandra D. Silvestri

Adam Singer

Harold Smethills

Roy C. Smith

Emily Spitzer

James Stuart Jr.

James C. Tyree

Peter Wilson

Anne Zaring

senior staffPresident and Chief Executive Officer Jeffrey Brewer

Chief Human Resources Officer Gerri Feemster Bostick, SPHR

Executive Vice President, Development Mania Boyder

Vice President, Research Darlene Deecher, Ph.D.

Senior Vice President, Scientific Affairs Robert A. Goldstein, M.D., Ph.D.

Assistant Vice President, Cure Therapies Julia Greenstein, Ph.D.

Senior Vice President, Strategic Alliances Karin Hehenberger, M.D., Ph.D.

Chief Scientific Officer Richard A. Insel, M.D.

Vice President, Internal Audit Gil King

Vice President, Individual, Major and Planned Giving Jamie Klobuchar

Assistant Vice President, Treatment Therapies Aaron Kowalski, Ph.D.

Vice President, Business Development Michael Malekoff

Vice President, Government Relations Cynthia Rice

Senior Vice President, Marketing and Communications Claire Schultz

Chief Financial Officer & Assistant Treasurer Edward Sebald

Chief Operating Officer Lawrence A. Soler, Esq.

Chief Information Officer James Szmak

DIReCTORs, ChANCeLLORs & seNIOR sTAFF

Produced by Torrisi Design Associates, Inc. NYC

26 Broadway, 14th Floor New York, NY 10004 800-533-CURE 212-785-9500 www.jdrf.org

Documents

JDRF 2010 Annual Report · 2015-08-30 · JDRF is committed to delivering better treatments – and ultimately a cure – to people with type 1 diabetes. Over its 40 years, JDRF has